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SUMMARY 
 
Prion diseases or transmissible spongiform encephalopathies (TSEs) are lethal 
infectious diseases affecting humans and a variety of animal species. The prevailing 
hypothesis suggests that the infectious disease-causing particle termed “the prion” 
consist of a misfolded form of the normal cellular prion protein (PrPC) that has been 
converted into a disease-associated form (PrPSc). It is believed that PrPSc, either as a 
monomer or as a highly order aggregate, catalyses the conversion of PrPC into PrPSc 
and thus becomes self-propagating (i.e. infectious). The molecular composition of 
PrPSc, the mechanism of conversion and how the conversion leads to pathology is not 
clear. None-the-less, all familiar TSEs display mutations within the Prnp locus and 
ablation of Prnp confers resistance to TSEs in mice. 
In the main part of the thesis I investigated the role of microglia in prion disease. In 
order to do so, I first established a novel assay allowing for prion replication in 
organotypic cerebellar slice cultures. These cultures are thin slices of living cerebellar 
brain tissue that can be kept alive for up to 26 weeks ex vivo. In prion infected 
cultures prepared from mice over-expressing PrPC, PrPSc could be recovered as early 
as 3 weeks post-inoculation. I transmitted the prion-infected slices to a secondary 
prion transmission assay that allowed us to determine the amount of infectivity 
generated within the slices. The amount of infectivity recovered from organotypic 
cerebellar slices 5 weeks post-inoculation was equal to what could be recovered from 
a terminally scrapie-sick mouse 150 days post-inoculation. No infectivity was 
recovered from prion-exposed Prnpo/o slices. I could show that the localization and 
the replication properties of PrPSc in our cultures behaved similar to what is seen in 
vivo.  
Next, I utilized a transgenic mouse model (CD11b-HSVTK) that allowed for the 
conditional depletion of microglia. Microglia could be ablated from CD11b-HSVTK 
slices within 2 weeks with no obvious consequences for other neural cells 
populations. A 15-fold increase in prion infectivity was observed 30 days post-
inoculation in prion infected microglia-depleted slices relative to non-depleted slices. 
This increase in prion-infectivity could blocked by adding back exogenous 
macrophages to microglia-depleted tissue. In addition, depletion of microglia allowed 
for an infection of the tissue with an amount of prions that would normally not lead to 
            SUMMARY      
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an infection. Our results strongly suggests that microglia play a role in inhibiting 
prion replication and could represent an important central nervous system (CNS) anti-
prion defense. 
For the second part of the thesis I developed a novel method to distinguish between 
the inoculum used to infect cells (input) and the newly synthesized prions that can be 
recovered from prion infected cells (output). This technique allows for the study of 
prion-replication in non-diving cells without the interference of persisting residual 
inoculum, which could interfere with the interpretation of the experiment. I use 
homogenates of prion-infected C4/C4 mice that express a deletion mutant of the prion 
protein lacking the octa-repeat region (ΔPrP32-93). Brain homogenates from these 
mice can be used to infect cultures expressing the full-length prion protein. PrPSc is 
subsequently detected with an antibody recognizing a linear epitope in the octa-repeat 
region of PrPC. This epitope is absent in the inoculum, but present in the newly 
generated PrPSc, allowing for a specific detection of de novo replicated PrPSc. This 
allows for the investigation of which post-mitotic or slowly dividing cells can be 
prion infected. I show with the technique that cerebellar granule neurons and 
astrocytes can be infected. I also show that I cannot infect microglia, most likely due 
to their low expression of PrPC. I am currently testing which other CNS or peripheral 
nervous system (PNS)-derived cells can support prion replication.  
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Zusammenfassung 
 
Prionenerkrankungen oder transmissible spongiforme Enzephalopathien (TSE) sind 
tödlich verlaufende, übertragbare Erkrankungen, die eine Vielzahl verschiedener 
Spezies befallen können. Eine vorherrschende Hypothese besagt, dass das infektiöse, 
die Erkrankung auslösende Agens – auch  als „Prion“ bezeichnet – aus fehlgefaltetem 
normalem zellulärem Prionprotein (PrPC) besteht, welches in die Erkrankungs-
assoziierte Form (PrPSc) konvertiert worden ist. Man nimmt an, dass PrPSc, entweder 
als Monomer oder als Aggregat hoher Organisationsstufe, die Konversion von PrPC 
zu PrPSc katalysiert und auf diese Weise im infektiösen Sinne selbst-replizierend wird. 
Weder die molekulare Zusammensetzung von PrPSc und der Mechanismus der 
Konversion, noch der Zusammenhang zwischen der Umfaltung und den zu 
beobachtenden pathologischen Veränderungen sind bekannt. Allerdings weisen alle 
familiären Fälle von TSE Mutationen im Prnp Lokus auf und die genetische 
Ausschaltung („knockout“) von Prnp bewirkt in Mäusen eine Resistenz gegen TSE. 
Der Hauptteil der Doktorarbeit befasst sich mit der Rolle von Mikrogliazellen in 
Prionerkrankungen. Als Vorraussetzung hierfür musste zunächst ein neuer Assay 
entwickelt werden, um die Replikation der Prionen in organotypischen zerebellären 
Gewebskulturen („slice cultures“) zu untersuchen. Bei diesen Kulturen handelt es sich 
um dünne Schnitte aus lebendem zerebellärem Gewebe, welches ex vivo bis zu 26 
Wochen am Leben erhalten werden kann. In prioneninfizierten slice cultures aus PrPC 
überexprimieren Mäusen, konnte PrPSc bereits 3 Wochen nach Inokulation 
nachgewiesen werden. Die mit Prionen infizierten slice cultures wurden nachfolgend 
in einem weiteren Prionen Transmissionsexperiment untersucht, welches erlaubt die 
Menge an in den Kulturen erzeugter Infektiosität zu bestimmen. Die Menge an 
Infektiosität, welche nach 5 Wochen in den slice cultures nachgewiesen werden 
konnte, entsprach derjenigen einer terminal an Scrapie erkrankten Maus 150 Tage 
nach Inokulation. Dagegen fand sich keine Infektiosität in Prion exponierten Kulturen 
aus Prnpo/o Mäusen. Es zeigte sich, dass PrPSc in den Kulturen eine ähnliche 
räumliche Verteilung und Replikationseigenschaften wie in der in vivo Situation 
aufwies.  
Im weiteren Verlauf wurde ein transgenes Mausmodell (CD11b-HSVTK) verwendet, 
in welchem eine getriggerte Depletion von Mikrogliazellen möglich ist. 
               ZUSAMMENFASSUNG      
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Mikrogliazellen konnten aus Kulturen von CD11b-HSVTK Mäusen innerhalb von 
zwei Wochen ohne offensichtliche negative Konsequenzen für andere (neuronale) 
Zellpopulationen depletiert werden. In infizierten Mikroglia-depletierten Kulturen 
konnte 30 Tage nach Inokulation – im Vergleich zu nicht depletierten Kulturen – ein 
15-facher Anstieg der Prion-Infektiosität beobachtet werden. Der Anstieg der Prion-
Infektiosität konnte durch Zugabe von exogenen Makrophagen aufgehoben werden. 
Zusätzlich konnten durch die Depletion von Mikrogliazellen die Kulturen schon mit 
einer Prionendosis infiziert werden, die normalerweise nicht für eine Infektion 
ausreichen würde. Die Ergebnisse legen nahe, dass Mikrogliazellen an einer 
Hemmung der Replikation von Prionen beteiligt sind und einen wichtigen 
Abwehrmechanismus des ZNS gegen Prionen darstellen.  
Im zweiten Teil meiner Doktorarbeit habe wurde eine neue Methode entwickelt, um 
zwischen dem für die Zellinfektion benutzten Inokulum (Input) und den neu 
synthetisierten Prionen, die in infizierten Zellen nachgewiesen werden können 
(Output), zu unterscheiden. Diese Technik erlaubt es, die Replikation von Prionen in 
postmitotischen Zellen ohne den Einfluss von noch vorhandenem restlichem 
Inokulum, welches die Interpretation des Experimentes beeinträchtigen könnte, zu 
untersuchen. Hierzu wurden Homogenate von Prionen infizierten C4/C4 Mäusen, 
welche eine Deletionsmutante des Prionproteins ohne die Oktarepeatregion (ΔPrP32-
93) exprimieren, verwendet. Hirnhomogenate von diesen Mäusen können zur 
Infektion von Kulturen benutzt werden, welche das Volllängen Prionprotein 
exprimieren. In der Folge kann PrPSc mit einem Antikörper detektiert werden , der 
gegen ein lineares Epitop in der Oktarepeatregion von PrPC gerichtet ist. Dieses 
Epitop fehlt im Inokulum, ist allerdings im neu entstandenen PrPSc enthalten, was 
einen spezifischen Nachweis von de novo erzeugtem PrPSc ermöglicht. Somit ist es 
möglich zu untersuchen, welche postmitotischen oder sich langsam teilenden Zellen 
mit Prionen infizierbar sind. Mit dieser Technik konnte gezeigt werden, dass 
Neuronen der Granularzellschicht des Kleinhirnkortex und Astrozyten mit Prionen 
infiziert werden können. Ausserdem wurde nachweisen, dass Mikrogliazellen nicht 
infizierbar sind, was am wahrscheinlichsten an den geringen Expressionsspiegeln von 
PrPC in diesem Zelltyp liegt. Gegenwärtig wird untersucht, welche weiteren Zellen 
des ZNS oder des peripheren Nervensystems (PNS) die Replikation von Prionen 
unterstützen können. 
       DEFINITIONS
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DEFINITIONS 
 
Prion: Agent of transmissible spongiform encephalopathy (TSE), with 
unconventional properties. The term does not have structural implications other than 
that a protein is an essential component. 
 
'Protein-only' hypothesis: Maintains that the prion is devoid of informational nucleic 
acid, and that the essential pathogenic component is protein (or glycoprotein). Genetic 
evidence indicates that the protein is an abnormal form of PrP (perhaps identical with 
PrPSc). The association with other 'non-informational' molecules (such as 
glycosaminoglycans, or maybe even short nucleic acids) is not excluded. 
 
PrPC: The naturally occurring form of the mature Prnp gene product. Its presence in a 
given cell type is necessary, but not sufficient, for replication of the prion. 
 
PrPSc: An 'abnormal' form of the mature Prnp gene product found in tissue of TSE 
sufferers, defined as being partly resistant to digestion by proteinase K (PK) under 
standardized conditions. It is believed to differ from PrPC only (or mainly) 
conformationally, and is often considered to be the transmissible agent or prion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Aguzzi and Weissmann (Aguzzi and Weissmann, 1997)
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ABBREVIATIONS 
BSE Bovine spongiform encephalopathy 
CJD Creutzfeldt-Jakob disease 
CNS Central nervous system 
CWD Chronic wasting disease 
DPI Days post-inoculation 
DIV Days in vitro 
FFI Fatal familial insomnia 
GCV Ganciclovir 
GFAP Glial fibrillary acidic protein 
GPI glycosylphosphatidylinositol 
GSS Gerstmann-Sträussler-Scheinker disease 
IB4 Isolectin-B4 
LPS Lipopolysaccharide 
MBP Myeline basic protein 
MIP-1β Macrophage inflammatory protein-1 beta 
OHSCs Organotypic hippocampal slice cultures 
PI Propidium Iodide 
PK Proteinase K 
PNS Peripheral nervous system 
POSCA Prion organotypic slice culture assay 
PrPC Cellular prion protein 
PrPSc Scrapie-associated prion protein 
RML Rocky Mountain laboratory strain  
SCA Scrapie cell assay 
SCEPA Scrapie cell assay in end point format 
SCI50 Slice culture infectivity units  
TCI50 Tissue culture infectivity units 
TK Herpes simplex virus thymidine kinase 
TNF Tumor necrosis factor 
TSE Transmissible spongiform encephalopathy 
vCJD Variant Creutzfeldt-Jakob disease
                          INTRODUCTION
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Introduction 
 
 
Transmissible spongiform encephalopathies 
Prion diseases are fatal neurodegenerative disorders, also known as transmissible 
spongiform encephalopathies, that affect humans and variety of captive and wild 
animals (Aguzzi, 2006). Known animal TSEs are restricted to a small number of 
species, including naturally occurring sheep and goat scrapie (Cuille and Chelle, 
1939), but also chronic wasting disease (CWD) of mule deer and elk (Williams and 
Young, 1980), bovine spongiform encephalopathy (BSE) (Hope et al., 1989) and 
transmissible mink encephalopathy (Marsh and Hadlow, 1992). Human TSEs include 
variant and ‘classical’ Creutzfeldt-Jacob diseases (CJD) (Gibbs et al., 1968), fatal 
familial insomnia (FFI) (Medori et al., 1992), Gerstmann-Sträussler-Scheinker 
syndrome (GSS) (Gajdusek, 1977) and Kuru (Gajdusek et al., 1966). 
TSEs can be classified as either familial dominantly inherited diseases, acquired 
diseases (acquired by exposure to infectious material) or as sporadic diseases if a 
genetic or infectious cause cannot be identified. Major neuropathological hallmarks of 
TSEs are extensive spongiosis, neuronal cell loss in the central nervous system, 
gliosis (DeArmond et al., 1993), and deposition of amyloid plaques or amorphous PrP 
aggregates (Bendheim et al., 1984; DeArmond et al., 1985; Manuelidis et al., 1997). 
The accumulation in the brain of the host-encoded prion protein PrP that is designated 
PrPSc, an abnormally folded form of the normal cellular prion protein (PrPC) is the 
defining trait of TSEs. Although the exact structure and composition of the 
transmissible prion has not been unequivocally demonstrated, the major component of 
the prion agent (from proteinaceous infectious only) seems to be devoid of 
informational nucleic acids and is composed mainly of PrPSc.  
Although many similarities to other neurodegenerative protein misfolding diseases 
such as Alzheimer’s, Huntington’s and Parkinson’s disease has been described 
(DeArmond, 1993; Aguzzi and Haass, 2003), prion diseases are unique in that they 
are transmissible. Experimental disease models in species ranging from mice to cows 
and elk are mainly based on the observation that injection of homogenates of brain or 
                          INTRODUCTION
_____________________________________________________________________ 
                                                                                                                             13
 
spleen tissue from affected individuals into another individual of the same species will 
typically reproduce the disease. This important fact was recognized more than half a 
century ago in the case of scrapie affecting sheep and goats (Cuille and Chelle, 1939). 
Prion diseases in animals 
Naturally occurring scrapie has been recognized in sheep and goats since the 18th 
century (Aguzzi, 2006). Initially the disease was dubbed “tremblante” in French 
because of the tremor syndrome developed by these animals. Recently several other 
widespread occurrences of TSEs have been observed in other wild or domesticated 
species of animals. Chronic wasting disease is a prion disease of captive and free-
ranging mule deer and elk. The first cases of CWD were reported in the late 1960s in 
Colorado and the current status is that the disease has spread across most of the US 
and into Canada with no means of limiting the spread of disease (Sigurdson and 
Aguzzi, 2007). In the UK, a previously unrecognized neurological disease in cattle 
was first defined in 1986: the pathologic changes in brains were similar to those 
characteristic of TSEs. This new form of TSE, called bovine spongiform 
encephalopathy or more popularly, mad-cow disease, rapidly developed into a major 
epidemic, primarily in the UK but also in other neighboring European countries. The 
emergence of BSE was possibly caused by transmission of sheep Scrapie to cattle, 
through infected feed prepared from rendered carcasses (Wilesmith, 1988). An 
alternative hypothesis is that feed prepared from cattle with BASE, an atypical 
possibly sporadic form of BSE, could have been the cause of the UK outbreak 
(Capobianco et al., 2007). The routes for transmission of prions in scrapie and CWD 
remain elusive, but recently several possible routes of horizontal and lateral 
transmission has been described, such as transmission through urine in animals 
suffering from nephritis (Seeger et al., 2005), through milk in animals with mastitis 
(Ligios et al., 2005), and through saliva (Mathiason et al., 2006).  
Prion diseases in humans 
All prion diseases can be subdivided into inherited, sporadic and acquired forms. 
Several different human neurodegenerative conditions have been recognized as prion 
diseases: Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome, Kuru, 
fatal familial insomnia and cases of sporadic fatal insomnia. Most cases of human 
                          INTRODUCTION
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prion disease are sporadic CJD (roughly 85 %). Sporadic CJD occur at a rate of 1-3 
cases per million inhabitants per year across the world, with an equal incidence in 
men and women. The etiology of sporadic CJD is unknown, but different hypothesis 
propose that sporadic CJD could be triggered by somatic Prnp mutations, or that a 
spontaneous conversion of PrPC into disease associated PrPSc occurs as a rare event, 
leading to further generation of PrPSc and ultimately disease. Homozygosity at a 
common coding polymorphism at codon 129 of Prnp encoding either methionine or 
valine predisposes to the development of sporadic and acquired CJD. Acquired 
conditions include diseases transmitted by dietary infections, such as Kuru (caused by 
human-to-human transfer through ritual cannibalism) and variant CJD (vCJD) (likely 
caused by bovine-to-human transfer) or by other infection routes like iatrogenic 
contact with infected material during treatment with purified human hormones or 
during brain surgery. Retrospective studies in subjects suffering from Kuru, showed 
that prion diseases typically exhibit a very long latency period (up to 50 years) 
between the time of infection and the clinical manifestation: this is the reason why 
these diseases were originally thought to be caused by “slow viruses” (Collinge et al., 
2006). About 15 % of human prion diseases are associated with autosomal dominant 
pathogenic mutations in the Prnp gene. Most pathogenic mutations in Prnp is thought 
to lead to an increased tendency of PrPC to convert into PrPSc, but not all disease 
causing Prnp mutations are associated with PrPSc and infectivity. 
The discovery of a variant form of CJD in the United Kingdom in 1996 was 
epidemiologically and experimentally linked to the widespread UK BSE epidemic in 
the 1980s and early 1990s. The indication that BSE is transmissible to different 
animal species, including humans, unlike previously characterized prion diseases such 
as sheep scrapie, has raised enormous public health concerns worldwide. Although it 
would appear that the annual new cases of vCJD has peaked (Aguzzi et al., 2007), all 
patients suffering from vCJD so far were homozygous for methionine at codon 129 of 
Prnp. Experiments in mice expressing different isoforms of human PrPC show that 
valine at codon 129 of Prnp inhibits transmission of BSE. Mice homozygous for 
methionine at codon 129 replicate BSE efficiently. Mice that are heterozygous for 
methionine and valine at codon 129 show a delayed onset of disease, but still develop 
clinical disease nonetheless (Wadsworth et al., 2004). Whether this is an indication 
that we will see a delayed vCJD outbreak in humans heterozygous at codon 129 is 
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still unknown and only time will tell. To make matters worse, transmission of vCJD 
through donated blood from a donor, who went on to develop vCJD years after 
donating blood, to multiple recipients was recently described (Llewelyn et al., 2004; 
Wroe et al., 2006). This shows that vCJD transmit efficiently through blood and 
unfortunately no sensitive diagnostic method is available for detecting prions in 
blood, although many different assays are currently under development. The threat to 
public health and the emergence of new prion epidemics such as CWD and BSE has 
intensified research efforts to understand the molecular basis of prion diseases, 
understand their transmission between and within species, improve methods of 
diagnosis, and develop therapeutic strategies for treatment and prevention of disease. 
 
Prion conversion reaction 
The protein-only hypothesis, the prevailing hypothesis on the nature of the infectious 
prion, proposes that the infectious disease causing agent consists essentially of PrPSc, 
an abnormally folded, protease resistant, β-sheet rich isoform of the normal cellular 
prion protein, denoted PrPC (Prusiner, 1991). The notion that a protein might be the 
infectious agent causing TSEs was first proposed by Griffith (Griffith, 1967). This 
idea was later substantiated by Stanley Prusiner who suggested that this protein 
(discovered and named by him) was the prion protein, work for which he was 
rewarded the Nobel price (Prusiner, 1982). Subsequently the prion concept was 
further refined by Charles Weissmann (Weissmann, 1991) to mean an infectious 
protein that does not contain any informational nucleic acids, and its infectivity 
propagates by recruitment and “autocatalytic” conformational conversion of cellular 
prion protein into disease-associated PrPSc (Aguzzi et al., 2007).  
The amount of evidence speaking in favor of the prion-only hypothesis is abundant, 
but several key observation bears mentioning. First of, familial cases of human TSEs 
are all characterized by Prnp mutations linking Prnp to prion disease (Prusiner et al., 
1998). Indeed knockout mice carrying a homozygous deletion of the Prnp gene that 
encodes PrPC, fail to develop disease upon inoculation with infectious brain 
homogenate (Büeler et al., 1993). Excitingly, it has now been shown that de novo 
prion infectivity can be generated by sonicating a mixture of lipids, synthetic poly-
anions, and native PrPC purified from normal hamster brain (Deleault et al., 2007). 
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External confirmation of these results should lay to rest the debate about the validity 
of the prion-only hypothesis and shift the focus of research to the nature of the 
infectious prion agent. 
Prion diseases are associated with abundant accumulation of PrPSc in the CNS. PrPSc 
and PrPC were found to share a similar amino acid structure but no known covalent 
modifications has been found to differentiate the 2 proteins (Stahl et al., 1993). It is 
therefore proposed that PrPSc is a posttranslational derivative of PrPC having acquired 
a different 3-dimensional (3D) conformational structure and that pathologic PrPSc 
operates as a template promoting further conversion of PrPC. The resolution of the 3D 
structure by NMR of mouse, hamster and human PrPC (Riek et al., 1996; James et al., 
Template-directed refolding model 
Nucleation model 
a 
b 
Figure 1. Models for the Conversion of PrPC into PrPSc
(a) The ‘Template-directed refolding model’ postulates an interaction between PrPSc and PrPC, which is 
subsequently induced to transform itself into PrPSc. A high energy barrier may prevent spontaneous 
conversion of PrPC into PrPSc. (b) The ‘nucleation-polymerization model’ proposes that PrPC and PrPSc 
are in a reversible thermodynamic equilibrium. Only if several monomeric PrPSc molecules form a 
highly ordered seed, can further monomeric PrPSc entities be recruited and eventually generate larger 
aggregates with an amyloid structure. Within such a crystal-like seed, PrPSc becomes stabilized. 
Fragmentation of PrPSc aggregates increases the number of nuclei, which can then recruit further PrPSc 
and thus replicate the prion agent (adapted from (Aguzzi and Polymenidou, 2004)). 
___________________________________________________________________________________ 
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1997; Hosszu et al., 1999) and the development of newer techniques to study 
amyloids such as hydrogen/deuterium exchange has provided some suggestions for a 
possible conversion mechanism (Lu et al., 2007). However, the high increase in β-
sheet content of PrPSc (43 %) compared to PrPC (only 3 %) has prevented the 
generation of a high resolution structure of PrPSc and the understanding of the 
conversion event itself. The structural transition is accompanied by profound changes 
in the physicochemical properties of the prion protein. While PrPC
 
is soluble in mild 
detergents and sensitive to proteinase K (PK) digestion, PrPSc
 
forms insoluble 
aggregates and is partially resistant to PK (Bolton et al., 1982; Oesch et al., 1985; 
Meyer et al., 1986). Attempts to purify PrPSc by fractionation and correlating the mass 
of the purified (mainly) protein complexes to the infectivity of the samples, indicates 
that the most infectious prion particle has a mass corresponding to 14-28 PrP 
molecules (Silveira et al., 2005). 
Nonetheless, 2 different hypothesis have been put forward to explain the pathological 
conversion of PrPC into PrPSc. The first model, “the template-directed refolding 
model”, postulates that a strong kinetic energy barrier prevents PrPC from 
spontaneously misfold into PrPSc. Overcoming of the high energy barrier is only 
possible in the presence of a misfolded PrPSc template. Sporadic CJD may come about 
through a very rare spontaneous conversion of PrPC to PrPSc, giving rise to a template-
assisted conversion cascade. Possibly with the help of a chaperone (designated protein 
X) (Telling et al., 1995) or a non-protein molecule such as glucosaminoglycans or 
short nucleic acids (Priola et al., 2003).  
The second hypothesis “the nucleation model” proposes that PrPC and PrPSc exist in a 
natural equilibrium heavily shifted towards PrPC, so that only minute amounts of 
PrPSc would coexist with PrPC. PrPSc is stabilized by polymerizing onto a crystal-like 
seed, fibril or aggregate of PrPSc. Seed formation is an extremely slow event, but once 
a seed has been generated, monomers can add on rapidly. According to this 
“nucleation hypothesis” (Jarrett and Lansbury, 1993), the aggregated state and not 
necessarily the misfolded form of PrP, would be an intrinsic property of infectivity. 
Monomeric PrPSc would be harmless, but it would be prone to incorporation into 
nascent PrPSc aggregates leading to disease. However, both models fail to explain 
some aspects of TSEs, suggesting that component might be missing in the equation. 
Mainly, both models fail to explain that if spontaneous conversion of PrPC to PrPSc or 
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the formation of a PrPSc seed is a rare, but random event, why then does sporadic 
TSEs occur exclusively in elderly patients? If it was a truly random event, sporadic 
CJD should occur both in young, as well as in elderly people, which is clearly not the 
case. The missing part of both models could be a cellular clearing mechanism capable 
of PrPSc removal. An age-related failure of this system combined with the stochastic 
generation of PrPSc could then lead to the formation of seeds and the pathological 
manifestation of disease. However, no genetic or experimental evidence exist for such 
a mechanism.  
Because PrPC can undergo disease-associated structural modifications that do not 
impart protease-resistance, the term PrPSc has more recently been used to denote 
protease-sensitive pathological PrP variants (Safar et al., 2002). In this thesis PrPSc 
refers exclusively to protease-resistant PrP and the term ‘prion’ is used to described 
the infectious prion agent (as measured by transmission experiments). 
 
Prion pathogenesis  
The mechanisms of prion pathogenesis leading to gliosis, spongiosis, neuronal cell 
loss and clinical signs are not yet understood. Mice devoid of PrPC do not show any 
overt behavioral phenotype or signs of neurodegeneration (Büeler et al., 1992), 
suggesting that prion diseases are not caused by a loss-of-function associated with 
PrPC. Indeed the absence of PrPC, abolishes prion replication and clinical signs upon 
intracerebral inoculation with prions (Büeler et al., 1993). 
Clearly PrPC expression is crucial for prion replication, but does cerebral 
accumulation of PrPSc in the extracellular space suffice to damage nervous cells? To 
answer this question, Brandner et al. (Brandner et al., 1996) transplanted wild-type 
and PrP overproducing neuroectodermal grafts into brains of PrP knockout mice. 
After intracerebral inoculation with prions, the grafts accumulated high levels of PrPSc 
and infectivity and developed typical histopathological changes associated with 
scrapie pathogenesis. In the surrounding PrP-deficient tissue, no pathological changes 
were detected even when substantial accumulation of PrPSc occurred, indicating that 
neuronal cytotoxicity of PrPSc is dependent on the expression of cellular PrPC by 
target cells. This was later confirmed in mice expressing a secreted form of PrPC 
termed ‘GPI-anchorless’ (a secreted PrP molecule lacking the 
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glycosylinositolphospholipid-anchor (GPI)) (Chesebro et al., 2005). While the mice 
replicated PrPSc upon prion inoculation, the mice did not develop histopathological 
changes, illustrating that membrane attachment of PrP is required for cellular toxicity. 
In addition, it was recently described that early signs of prion pathogenesis such as 
spongiosis and behavioral symptoms can be can be reversed by conditionally 
removing PrPC selectively in neurons after disease onset (Mallucci et al., 2003; 
Mallucci et al., 2007). All together this suggests that prion replication within neurons 
could be a target for anti-prion intervention strategies.  
 
The cellular prion protein 
PrPC expression pattern 
The cellular prion protein is highly conserved in mammals and has been identified in 
birds (Harris et al., 1993), in amphibian (Strumbo et al., 2001), in turtles (Simonic et 
al., 2000) and more recently in fish (Rivera-Milla et al., 2003), suggesting an 
important function of PrPC. Despite the lack of a phenotype in PrP-deficient mice, no 
naturally occurring Prnp null alleles have been described despite the notion that a 
negative evolutionary pressure exist, stemming from the susceptibility of Prnp-
expressing animals to prion disease (Mead et al., 2003).  
PrPC is highly expressed in the central nervous system, but it is also expressed at high 
levels in a broad range of peripheral tissues and cells including heart, skeletal muscle, 
kidney and lymphocytes (Dodelet and Cashman, 1998; Ford et al., 2002). 
Inflammatory conditions can induce ectopic PrPC expression and prion replication 
competence in organs that only express very low amounts PrPC under normal 
circumstances (Heikenwalder et al., 2005). In the central nervous system PrPC is 
expressed to a high extend on neurons, although it is also expressed by other neural 
cell lineages including astrocytes and oligodendrocytes (Moser et al., 1995). In 
contrast, microglia express almost no, if any, PrPC (Baker et al., 2002). 
Biosynthesis of PrPC 
The newly transcribed unprocessed mouse PrP polypeptide consists of 254 amino 
acids. A 22 amino acids N-terminal hydrophobic signal sequence (in mice and 
hamsters) directs PrP to the membrane of the endoplasmic reticulum (ER), where the 
                          INTRODUCTION
_____________________________________________________________________ 
                                                                                                                             20
 
signal peptide is removed. After ER translocation, 23 amino acids are removed from 
the C-terminus and replaced with a GPI-anchor (Stahl et al., 1987). Within the ER 
lumen, high mannose glycans are attached to the 25 kDa polypeptide on asparagines 
at residues 180 and 196 and processed to complex glycans during transport through 
the Golgi apparatus (Bolton et al., 1985). The mature form of PrPC is transported 
within secretory vesicles to the external cell surface to which it is anchored by the 
GPI-moiety. The presence of 1 out of the 2 glycosylations is sufficient for an 
appropriate PrP-trafficking, but the deletion of both glycosylations causes intra-
cellular accumulation of PrPSc (Cancellotti et al., 2005). In cell culture, most PrPC 
molecules undergo endocytosis and degradation via the lysosome or proteasome 
pathway (Caughey et al., 1989), but about 10-30 % of PrPC is shed into the medium 
(Borchelt et al., 1990). 
The physiological function of PrPC 
The expression of PrP on the cell surface as a GPI-anchored extracellular molecule 
suggest a role in cell adhesion, cell-cell interaction or as a signalling molecule. Mice 
ablated of PrPC was initially reported to lack any phenotype (Büeler et al., 1992).  
However, later reports suggested subtle alterations in hippocampal synaptic function 
(Collinge et al., 1994) and in circadian rhythm and sleep-pattern of PrP-deficient mice 
(Tobler et al., 1996). Post-developmental ablation of PrPC was also reported to lead to 
subtle alterations in hippocampal synaptic function, identical to what was seen in PrP-
null mice, excluding that compensatory developmental effects are masking a stronger 
PrP-related phenotype (Mallucci et al., 2002). Unfortunately, most of these results 
could not be reproduced by other groups (Herms et al., 1995; Lledo et al., 1996). PrPC 
was recently suggested to be important for the self-renewal of long-term repopulating 
haematopoietic stem cells (Zhang et al., 2006) and a positive regulator of neural 
precursor proliferation during developmental and adult neurogenesis (Steele et al., 
2006). The lack of understanding of the molecular action of PrPC and even more the 
relative mildness of the described alterations in animals devoid of PrPC renders it 
difficult to attribute a direct role to PrP in any of these functions. Furthermore, it begs 
the question as to why PrPC is evolutionarily conserved if animals live fine without it. 
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PART I 
_________________________________ 
 
Part I of my thesis is an extended version of the publication Falsig et al., Nature 
Neuroscience (2008). It also contains a modified figure from the publication of 
Heppner et al., Nature Medicine (2005), as well as unpublished data.  
Introduction 
Prion bioassays  
The most common technique for measuring prions consists of inoculating test 
material intracerebrally into susceptible “indicator” animals. Precise titer 
determinations require determination of end-point dilutions, and therefore very large 
numbers of indicator animals. The incubation time is inversely proportional to the size 
of the inoculum, allowing for a simplified incubation-time bioassay which sacrifices 
precision yet requires much fewer animals (Prusiner et al., 1982). Conversely, these 
assays require observation periods that often span the entire natural life of indicator 
animals, as small amount of infectivity may go along with exceedingly long 
incubation times. This is impractical and very expensive. In addition, minimizing the 
numbers of animals used for titration would reduce the suffering wrought by 
experimental prion infections. 
The introduction of the scrapie cell assay in end-point format (SCEPA) has eliminated 
some of the concerns listed above, and has allowed for a dramatic acceleration of 
infectivity assays (Klohn et al., 2003). Here, cells are exposed to end-point titrations 
of prions and are subsequently passaged several times. Prion titers are derived by 
counting PrPSc-positive tissue culture wells. Although the SCEPA does not require 
inoculation of animals, it is biologically equivalent to animal bioassays in that it 
detects actual transfer of prion infectivity from test materials to susceptible cells. 
However, the SCEPA suffers from 2 major limitations. Firstly, the infection of 
cultured cells reproduces only certain aspects of the in vivo situation. The reactions of 
the CNS to a prion infection involve multiple, highly diverse cell types such as 
neurons, astrocytes, oligodendrocytes, and microglia. This diversity cannot be 
reproduced in the SCEPA which is based on monoclonal, highly homogeneous cells. 
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Secondly, the spectrum of cell lines that have been identified as susceptible to prion 
infection in vitro is very limited. This presently restricts the applicability of the 
SCEPA to a small subset of mouse-adapted prion strains. These 2 limitations may be 
interdependent, since the molecular machinery necessary for overcoming strain and 
species barriers may reside in cells different from those replicating prions most 
efficaciously. Be as it may, infectivity titrations of any prion variant that does not 
efficiently infect cultured cells still require animal bioassays.  
The prion strain phenomena 
Prion strains are infectious isolates that when transmitted into identical hosts exhibits 
different prion disease phenotypes. The strain characteristics can differ in incubation 
times, histological lesion profiles, organ-tropism (e.g. lympho-tropism), biophysical 
characteristics and neuronal target areas (Aguzzi et al., 2007). 
Strain-specific properties might be obtained by PrPSc adopting different specific 
disease associated conformations, all of which can transmit and cause disease, with 
the disease phenotypes being determined by the specific conformation of PrPSc in the 
donor inoculum. Circumstantial evidence indicates that strain phenotypes might be 
encoded within different PrPSc conformations with distinct properties. This is 
supported by evidence suggesting that different prion strains have different stability 
against chaotropic salts and heat (Safar, 1998) and susceptibility to digestion with PK. 
In addition, the site of protease digestion can vary with different prion strains. 
Various, naturally occurring, BSE and CJD cases exhibit distinct running patterns on 
western blots after digestion with PK (Casalone et al., 2004; Zanusso et al., 2004). 
Different strains can be cleaved with PK a different sites in the N-terminus (Zanusso 
et al., 2004), suggesting a difference in the accessibility of the N-terminal part of the 
PrPSc molecule, supporting the idea that PrPSc conformation can encode strain 
phenotypes. Of note, it has been shown that different strain phenotypes can co-exist 
within the same individual (Polymenidou et al., 2005; Yull et al., 2006). However, the 
final proof that conformational variants of PrPSc represent the biological basis of prion 
strains is still amiss. Other biochemical traits of strains can be differences in the 
glycosylation patterns (i.e. the ratio of un-, mono- and diglycosylated forms of PrP) 
(Collinge et al., 1996). It was recently suggested that the ratio of distinct glycoforms 
may determine the structure of the infectious seed and thus confer strain properties 
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(Collinge, 2005). In addition, certain aspects of the strain properties are encoded by 
host-encoded PrPC (Nonno et al., 2006). 
As described above, various prion cell culture assays, based upon clones of cells 
selected for an efficient prion replication, are highly selective in which experimental 
prion strains they can replicate (Klohn et al., 2003; Solassol et al., 2003). Recently, 
primary neuronal cell cultures have been reported to display a broader selectivity 
towards different strains, showing properties similar to transmission of prions into 
mice (Cronier et al., 2007). Screening the susceptibility of any new prion assay to a 
collection of different strains therefore is a crucial parameter. 
The role of microglia in prion diseases 
Microglia, a CNS cell of myeloid origin, is considered the main immune cell of the 
brain. One of the primary roles of microglia is to act as a sentinel, detecting and 
responding to early signs of cellular damage or infection in the brain (Nimmerjahn et 
al., 2005). When damage has been detected, microglia can differentiate into various 
phenotypically distinguishable microglia types, depending of the type of stimuli they 
encounter. The distinction between the microglia phenotypes are not well described 
and appear to be somewhat overlapping. In general, microglia can be phagocytic 
(microglia capable of eating damaged cells, protein aggregates or pathogens), pro-
inflammatory (releasing large amounts of pro-inflammatory cytokines, chemokines 
and reactive oxygen species) and neuroprotective (releasing neurotrophic factors and 
supporting CNS regeneration) (Schwartz et al., 2006). It is believed that activated 
microglia contribute directly to the progression of prion pathology by releasing 
inflammatory and neurotoxic factors (Brown et al., 1996; Dandoy-Dron et al., 1998; 
Baker and Manuelidis, 2003; Baker et al., 2004; Kercher et al., 2007). However, anti-
inflammatory properties of microglia have also been reported in certain prion models 
(Boche et al., 2006). Activation of microglia in prion infections is very extensive and 
precedes significant neurodegeneration (Manuelidis et al., 1997; Williams et al., 
1997). Microglia are abundantly associated with prion plaques, and PrPSc can 
sometimes be found within microglia (Manuelidis et al., 1997; Andreoletti et al., 
2002). Hence microglia may exert either precipitating or defensive effects in prion 
pathogenesis.  
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Outline of this work 
Here I have investigated whether ex vivo cultures of tissues derived from wild-type or 
from genetically modified mice might help circumventing the limitations described 
above. I found that organotypic cerebellar slice cultures efficiently and rapidly 
amplify PrPSc after exposure to prions. This paradigm allows for dissecting CNS 
pathologies in a complex cellular environment which is morphologically very similar 
to the intact brain. The sensitivity of the prion organotypic slice culture assay 
(POSCA) was marginally lower than that of the SCEPA. While the POSCA makes 
use of animals as the original tissue donors, many genetically identical slices can be 
produced from each individual mouse. Thus, genetic background differences of mice 
can be controlled by comparing samples prepared from the same individual mouse. In 
addition, POSCA are capable of replicating a large variety of prion strain of scrapie 
and BSE origin, including strains that do not replicate in the SCEPA.   
Since POSCA allows for the study of prion replication in a complex cellular 
environment the assay is ideally suited to study the function of microglia in prion 
diseases. I found that complete microglial ablation from slices generated from 
CD11b-HSVTK transgenic mice led to a dramatic increase in prion titers and PrPSc 
deposition. These data suggest that microglia plays a significant role in containing 
prion loads during the course of prion infections. 
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RESULTS 
Prion Organotypic Slice Culture Assay 
Culture establishment 
In order to develop a slice culture based prion assay I utilized the membrane-insert 
based slice culture technique developed by Luc Stoppini (Stoppini et al., 1991).  
Various culturing conditions were tested, including the age of mice used for preparing 
slices, the method of slice preparation, culture medium compositions, as well as 
volume and frequency of media changing. The best results were consistently achieved 
when slices were prepared by vibratome sectioning, and were cultured on Millicell-
CM BioporeTM BTFE membranes. The full volume of medium was exchanged 3 
times each week. Firstly, I assessed the morphological integrity of slices by standard 
light microscopy and immunohistochemistry. These studies uncovered that slices 
could be kept in culture without losing their defining morphological traits, including 
expression of neuronal, astrocytic, and myelin markers (Figure 2). Some 
Figure 2. Morphological integrity of organotypic cerebellar slice cultures 
(a) A composite phase contrast image of an organotypic cerebellar slice 5 weeks in vitro. The image 
was generated from 7 independent images (5x magnification). Major morphological features were 
visualized by fluorescent microscopy. Slices were stained with (b) rabbit α-glial fibrillary acidic 
protein (GFAP) polyclonal antibody (astrocytes), (c) rabbit α-neurofilament-M polyclonal antibody 
(axons of Purkinje neurons), (d) rat α-myelin basic protein (MBP) IgG2a (myelin), (e) mouse α-
calbindin IgG1 (cell bodies of Purkinje neurons), (f) isolectin-B4 (microglia), and (g) mouse α-
parvalbumin IgG1 (GABAergic interneurons). 
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morphological features were slightly altered in our culture system. After 2 weeks in 
culture approximately 1-2000 microglia and a few fibroblasts migrated out of the 
tissue and onto the membrane. An increased GFAP expression was seen after 1 week 
in culture and astrocytes extended a few processes outside the tissue, however no 
astrocytes could be found outside the tissue. The various cell layers displayed a 
progressive spreading over time, but in general the tissue appeared morphologically 
intact (Figure 2).  
As prion infections are extremely slow processes in vivo, I reasoned that successful 
slice culture infection would crucially depend on the establishment of organotypic 
cultures with the greatest possible longevity, defined as the span of time during which 
cell death within slices does not rise above 5 %. Slice viability was assessed after 5 
weeks of culturing by propidium iodide (PI) permeability and DEVDase activity 
assays (Figure 3a-c). These assays measure the total extent of cell death and the 
Figure 3. Viability of cerebellar slice cultures 
(a) Time course of cell death induced by staurosporine treatment of cerebellar slice cultures 
cultured for 5 weeks in vitro. For generation of standardized positive controls, slices were cultured 
for 5 weeks and treated for different lengths of time with 5 μM staurosporine, a compound known 
to induce apoptotic death of neuronal cultures and PI incorporation (10 μg/ml) was measured (n = 
12). Slices were harvested and caspase-3 enzymatic activity was measured and normalized to 
protein contents (n = 3 pools of 4 slices). (b-c) Representative examples of images used for PI 
incorporation. 
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activation of executioner caspases. For control, slices were treated with staurosporine, 
which induces apoptotic death of granule neurons in culture. After 35 days in vitro, 
untreated slices showed 0.1 ± 0.02 % of the PI+ cells (or < 0.1 ± 0.02 % of the total 
tissue surface area) and 2.1 ± 0.6 % of the DEVDase activity levels seen in 
staurosporine-treated slices. I conclude that acceptable slice viability was maintained 
during a period of up to 5 weeks. Morphological and immuno-histochemical analyses 
with various markers of CNS constituents (see Figure 9) supported the latter 
contention.  
Prion infection of organotypic slice cultures 
The most broadly used assays for assessing the presence of prion infections rely on 
the differential susceptibility of PrPC and PrPSc to digestion with proteinase K (Bolton 
et al., 1982). The relative resistance of PrPSc to PK depends on prion strains, on the 
specific activity of PK, as well as on the composition and concentration of non-PrP 
contaminants. I therefore sought to determine the minimal conditions under which all 
PrPC present in slices would be fully degraded by PK. Protein lysates were prepared 
from 5-week old slices, subjected to digestion with various concentrations of PK, and 
their PrPC content was probed by western blotting (Figure 4a). Digestion of 20 μg 
protein lysate with 25 μg/ml PK (in a reaction volume of 20 μl, corresponding to 1 
mg/ml total protein) was found to ensure complete, reproducible removal of PrPC. 
These conditions were used in all subsequent experiments unless otherwise stated. 
In a first set of experiments, I inoculated 3-day old pups in vivo with a relatively large 
inoculum intracerebellarly (3 μl, 1 % RML6) using a Hamilton syringe. Cultures were 
prepared from inoculated pups at 9 days post-inoculation (dpi) (illustrated in Figure 
4b). Slices were cultured for 35 days in vitro, harvested, and assayed for PrPSc. No 
PK-resistant material was detected in any of 6 inoculated animals (Figure 4c). This 
outcome is consistent with multiple reports that prions undergo a long period of 
eclipse after intracerebral challenge, during which no infectivity can be recovered 
from the site of inoculation (Manuelidis and Fritch, 1996).  
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Figure 4. Cerebellar slice cultures prepared from infected mice 
(a) Western blotting of PK-digested slice culture homogenates from cultures 5 weeks in vitro. Various PK 
concentrations (25-100 μg/ml) were used to digest 20 or 80 μg protein lysate and detected with mouse 
anti-mouse PrPC IgG1 (POM-1). 20 μg/ml PK represents the minimal PK-concentration needed to fully 
digest PrPC in tga20TK slices. (b) Scheme depicting set-up for slice cultures of prion inoculated mice. 3-
day old tga20 or Prnpo/o pups were inoculated with 300 ng RML6 (3 μl, 1% brain homogenate) injected 
into the cerebellum. Cerebellar slices were prepared from 12-day old tga20 mice (9 days post-infection) 
and kept 35 days in vitro. (c) No PK-resistant material was observed in slices prepared from RML-treated 
tga20 mice or RML-treated prnpo/o mice. Abundant PK-resistant material was found in brain homogenates 
from a terminal scrapie-sick C57BL/6 mouse (Sc).   
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Next, I prepared organotypic cultures from non-inoculated 10-day old tga20TK (the F1 
offspring of tga20+/+ males crossed to CD11b-HSVTK females) and Prnpo/o pups. 
Groups of 10 slices were incubated with 1 ml of medium containing 20 mg of RML6 
homogenate (total brain homogenate from pooled, terminally sick CD-1 mice infected 
with RML prions). In order to minimize any potential toxicity stemming from cellular 
debris, exposure to the prion inoculum was carried out at 4°C in the presence of a 
non-selective glutamate receptor antagonist. The tissue was washed twice in 6 ml 
buffer and transferred to Millicell-CM BioporeTM BTFE membranes (illustrated in 
Figure 5a).  
After 5 weeks in vitro, slices were harvested and analyzed by western blot (Figure 
5b). An equal amount of brain material from the same terminally scrapie sick 
C57BL/6 mouse (Sc) was loaded onto the first lanes of all blots as a positive control. 
In tga20TK cultures infected with RML6, a characteristic triplet band pattern 
representing the di, mono and un-glycosylated forms of PrPSc was observed 
irrespectively of whether 25 or 50 μg/ml of PK was used. Levels were comparable to 
Figure 5. Establishment of in vitro prion infection 
(a) Scheme depicting set-up for in vitro infection of cerebellar slice cultures. Slice cultures were 
prepared from 12-day old mice and incubated with 20 mg RML6 (R) or mock brain homogenate (M) 
and kept 5 weeks in vitro. (b) Inoculated tissue was digested with 25 or 50 μg/ml PK. (c) Western 
blotting was performed on 20 μg protein digested with 25 μg/ml PK (+) or 10 μg non-digested protein 
(-).  
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those seen in the terminally scrapie sick C57BL/6 mouse (Figure 5b, lane 3,8,12). 
RML6-exposed slices deficient in PrPC expression, as well as slices exposed to 
uninfected brain homogenate (“mock” inoculum), did not show any PK-resistant 
material Figure 5b-c, lanes 6,7,9-11,13-15). A strong high-molecular band was 
observed in undigested RML-infected tga20TK samples, but not uninfected samples, 
showing an RML-induced shift in the post-translational modification of PrPC (Figure 
5b, lane 4,5).  
 
Correlation of inoculum dilution and PrPC template expression with PrPSc  
I examined the possibility that the PK-resistant PrP signal I observed might be due to 
residual inoculum adhering to slice constituents. I therefore performed titration 
experiments using varying amounts of inoculum. PrPSc was clearly detected in 
tga20TK cultures treated with as little as 1 μg RML6 homogenate per 10 slices (Figure 
6a, lane 15). In RML-treated cultures deficient for PrPC (n = 5) or in mock-treated 
cultures (n = 5) no PK-resistant material was observed even when the tissue was 
treated with 10 mg inoculum, showing that PrPSc was amplified at least 104-fold in 
tga20TK slices (Figure 6a, lane 6). The differences in PrPSc levels were not due to 
changes in PrPC expression (Figure 6b).  
To illustrate that replication had taken place in tga20TK cultures inoculated with 1 μg 
RML6, PrPSc levels were compared by Western blotting to a dilution curve of RML6 
diluted in uninfected brain homogenate. The total amount of protein recovered from 
the RML-infected slices was 400 μg, of which only 20 μg (5 %) were loaded onto the 
blot (Figure 7, lane 10). In the unlikely event that 100 % of the inoculum used to 
infect the cultures (1 μg) was recovered 5 weeks post inoculation; maximally 50 ng (5 
%) of inoculum could have been loaded onto the blot. The PrPSc band intensity for the 
RML-infected sample (containing at most 50 ng RML6) corresponded to the band 
intensity of a dilution containing 2000 ng RML6 (Figure 7, lane 5 compared to lane 
10). Since I detect 40 times more PrPSc than what I initially treated the tissue with, I 
conclude that an amplification of PrPSc indeed has taken place.  
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The expression levels of PrPC in host animals are negatively correlated to the 
incubation times in vivo (Büeler et al., 1993). In order to test for the impact of host 
PrP-expression levels on PrPSc replication I infected cultures from tga20TK 
(heterozygous for Prnp+/o and tga20+), heterozygous Prnp+/o mice, or tga20+ mice. I 
then compared PrPSc levels after inoculating the cultures with 1 mg RML6. I observed 
a clear correlation between host expression of PrPC (tga20TK > tga20+ > Prnp+/o, 
Figure 6d) and the amount of PrPSc observed in the cultures 5 weeks post-inoculation 
(tga20TK > tga20+ > Prnp+/o, Figure 6b).  
Figure 6. Titration of inoculum concentration and host PrPc expression 
Cultures from tga20TK and Prnpo/o mice were inoculated with various concentrations of RML6 or 
mock brain homogenate and cultured for 35 days prior to harvesting the tissue. (b) Non-digested 
samples from blot a. (c) Cultures prepared from tga20TK, tga20+, Prnp+/o or Prnpo/o were inoculated 
with 1 mg RML6 or mock. The tissue was harvested after 35 days in vitro. (d) Non-digested samples 
from blot c. 
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Figure 7. Sensitivity of western blot detection of PrPSc 
Tga20TK and Prnpo/o cultures were inoculated with 1 μg RML6 and after 35 DIV PrPSc levels were 
compared to a dilution curve of RML6 diluted in mock brain homogenate. Western blotting was 
performed on (+) 20 μg sample digested with PK (25 μg/ml) or (-) 10 μg undigested sample and 
detected with mouse anti-mouse PrPC IgG1 (POM-1). Legend for the RML-treated tga20TK sample 
indicates the total amount of input inoculum that theoretically could be in the sample assuming 
100% recovery of the input material. 
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Temporal increase in PrPSc deposition correlate with prion infectivity 
To conclusively prove bona fide prion replication, a time course experiment was 
performed using 100 μg RML6 per 10 slices (Figure 8a-b). 1 hr post-inoculation no 
residual inoculum was detected (Figure 8a-b, lane 4,5). After 14 days in vitro no 
indication of prion replication was observed, but after 3 weeks a definite PrPSc signal 
could be observed (Figure 8a-b, lane 10). No difference in PrPC expression was seen 
in the undigested cultures, showing that the difference in PrPSc levels were due to a 
difference in PK sensitivity rather than different expression of PrPC (Figure 8b).  
To test whether deposition of PrPSc goes along with prion replication, I assayed slice 
culture homogenates by SCEPA. Slices derived from tga20TK or Prnpo/o mice upon 
infection with RML6 (100 μg) for up to 35 days were homogenized and transmitted to 
N2a-PK1 cells. Tga20TK RML slice culture homogenates from the 4 and 5-week time 
points showed infectivity by SCEPA when transmitted at 10 and 1 μg protein/ml, but 
not at 0.1 μg protein/ml (in a volume of 300 μl/well, corresponding to 100 - 1 μg/ml 
RML6 homogenate) (Figure 8c). No infectivity was detected in Prnpo/o RML slice 
culture homogenates at any time point, or in tga20TK RML slices prior to 4 weeks in 
culture. At 1 μg/well the 5-week time point showed a significantly higher signal than 
the 4-week sample (One-way ANOVA with Bonferroni’s multiple comparison test,  p 
< 0.001). The number of TCI50 units in RML-infected tga20TK samples (1 TCI50 unit 
is the infectious dose required for infecting 50 % of the N2a-PK1 cultures) were 6.8 
TCI50 units/g protein, identical to what was measured in a calibration experiment with 
serial dilutions of RML6 (6.8 TCI50 units/g protein) (Figure 8c). This confirmed that 
both PrPSc and prions were amplified to a level similar to what can be detected in 
terminally sick mouse brain (Figure 8c).  
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Figure 8. Time course analysis of prion replication 
(a) Cultures from tga20TK (+) and Prnpo/o (-) pups were inoculated with 100 μg mock or RML6 and 
seeded onto membrane inserts. Tissue was harvested 1 h, 7, 21 or 35 days after seeding. (b) Non-
digested samples from blot a. (c) Time-dependent build up of prion titers in tga20TK (+++) and 
Prnpo/o (o/o) slices. RML-infected  (▼) or uninfected (Ø) brain homogenate and slice homogenates 
from the experiment reported in (a) were serially 10-fold diluted in uninfected brain homogenate, and 
infectivity was determined by transfer to PK1 cells. Exposure to 10 μg or 1 μg, but not 100 ng 
protein/ml from slices cultured for ≥28 days resulted in unambiguous replication of prion infectivity 
in PK1. In agreement with PrPSc determinations, no infectivity from any residual inoculum was 
detected as early as after 1 day of culture. Vigorous prion replication was detected in PK1 cells 
exposed to 10 µg/ml homogenate. 
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Localization of prion deposition and its impact on tissue integrity 
Having validated PI as a suitable cell death marker in our cultures, I evaluated PI 
retention after 5 weeks of prion infection. Surprisingly, prion infection did not exert 
any significant effect on viability (one-way ANOVA with Bonferroni’s multiple 
comparison test, p > 0.05, n = 12; Figure 9a-b). 
 
 
Figure 9. Impact of prion replication on tissue viability  
(a-c) Tga20TK (+++) and Prnpo/o (o/o) cultures were inoculated with 100 μg RML6 or Ø. 35 days 
post inoculation PI incorporation was analyzed. Data are presented as the average of 12 slices ± SD 
(b-c) Representative examples of images used for PI incorporation. 
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I assessed the morphological integrity of slices by standard light microscopy and 
immunohistochemistry at 1, 7, 21 and 35 days post inoculation. Neurons (calbindin), 
astrocytes (GFAP) and myelin (MBP) appeared intact. However, progressive 
broadening of cell layers became evident at 7-35 days of culture (Fig. 11a-c). 
Isolectin-B4 (IB4) and CD68+ microglia/macrophages increased over time, confirming 
slices underwent progressive microgliosis (Figure 10d-e, see also Figure 15 and 18). 
However, no difference in any of the above parameters was detected between RML-
treated Prnpo/o, RML-treated tga20TK or tga20TK slice cultures treated with uninfected 
brain homogenates at any given time point (Figure 10a-e).  
 
Figure 10. Impact of prion 
replication on tissue morphology 
 (a-e) Tga20TK (+++) and Prnpo/o 
(o/o) cultures were inoculated with 
100 μg RML or Ø. 1, 7, 21 or 35 
days post inoculation, the tissue was 
fixed in PFA and stained with (a) 
mouse α-Calbindin IgG1, (b) rat α-
MBP IgG2a, (c) rabbit α-GFAP 
polyclonal antibody, (d) IB4-
Alexa488 or (e) rat α-CD68 IgG2a. No 
difference was detected between 
RML-treated Prnpo/o, RML-treated 
tga20TK or mock-treated tga20TK 
cultures at any given time point (a-
c), data not shown). 
_____________________________ 
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The sites of PrPSc replication/deposition were evaluated using the histoblot technique 
(Taraboulos et al., 1992). Proteins were transferred from slice cultures to 
nitrocellulose membranes, and membranes were digested with 50 μg/ml PK. PrPSc 
was detected by immunoblotting (Figure 11a-c). To determine the localization of 
PrPSc, the major neuronal populations and the white matter was visualized by 
immunohistochemistry (Figure 11b). A strong PrPSc signal was observed in the 
molecular layer and in the Purkinje cell layers consistent with a high PrPSc deposition 
in granule cell axons, in Purkinje neurons and possibly in astrocytes. An intermediate 
Figure 11. Localization of prion replication 
(a) Tga20TK and Prnpo/o cultures were inoculated with 100 μg RML6 or mock homogenate. After 35 
days in vitro slice culture proteins were blotted onto a nitrocellulose membrane. The membrane was 
digested with 50 μg/ml PK and PrPSc was detected as described in materials and methods using the 
POM-1 antibody. (b) Uninfected cultures were stained with dapi (a chromatin-binding dye, blue) and 
antibodies against calbindin (Purkinje neurons, red) or myelin basic protein (myelin, white) to 
visualize the major morphological features of the cultures. (c) A larger magnification of (a) detailing 
the deposition of PrPSc. 
_________________________________________________________________________________ 
 
PART I               RESULTS 
_____________________________________________________________________ 
                                                                                                                             38
 
signal was observed in the granule cell layer, and a weak signal was present in the 
white matter (Figure 11c). 
Assay sensitivity 
To determine the infectious dose required for infecting 50 % of the slice cultures, I 
performed multiple infections at 1 and 0.1 μg RML6 per 10 slices. All cultures 
infected with 1 μg RML6 showed PK-resistant PrPSc, whereas no PK-resistant 
material was observed in cultures infected with 0.1 μg RML6 (Table 1, Figure 12 and 
data not shown). The dose at which 50 % of the slice cultures were infected (SCI50) 
was determined and 1 ml of 10 % RML6 (100 mg homogenate) contain > 5.7 log 
SCI50 calculated according to Kärber meaning that 1g brain yielded more than 6.7 log 
SCI50 (Kaerber, 1931).  
In order to compare our assay sensitivity with that of the commonly used bioassays 
we transmitted dilution series of RML6 into tga20 and CD-1 mice by intracerebral 
Figure 12. Determination of SCI50 
Tga20TK and Prnpo/o cultures were inoculated with 100 μg of scrapie strain 87V, 100 μg, 1 μg (n = 4) 
or 0.1 μg (n = 4) of RML6 and incubated for 35 DIV. Western blotting was performed on (+) 20 μg 
sample digested with PK (25 μg/ml) or (-) 10 μg undigested sample and detected with mouse anti-
mouse PrPC IgG1 (POM-1). PrPSc was observed in all tga20TK samples treated with 1 μg or more 
RML6 and in none of the samples treated with 0.1 μg RML.  
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inoculation or into the SCEPA (Table 1). The tga20 bioassay measured 9.9 log ID50 
units and CD-1 mice 9.3 log ID50 units/g brain homogenate. In comparison, the 
SCEPA showed a sensitivity of 7.7 log ID50/g (Figure 8c). 
 
 
 
 
 
 
 
 
 
Table 1: Comparison of prion assay sensitivity. The assay sensitivity of the tga20 and CD1 bioassay, 
SCEPA and POSCA was compared by performing endpoint titrations of RML6 in the various assays. 
The number of ID50 units (i.e. LD50 for tga20 and CD1 mice) per g of brain material were determined 
according to Kärber et al. Data points are presented as the number of infected animals/cultures out of 
the total number of animals/cultures treated with the inoculum. 
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The POSCA is applicable to a broad range of prion strains 
Theoretical considerations led us to predict that the POSCA may be applicable to a 
much broader range of prion strains than the current versions of the SCEPA. We 
tested this prediction by exposing POSCA slices to a variety of prion strains from 
different sources. Slices from tga20+/+ pups were treated with homogenates of the 2 
mouse-adapted scrapie strains, 79A and 139A (100 μg brain homogenate per 10 
slices), which are known to replicate in N2a-PK1 cells (data not shown). Infection of 
the tissue with either 79A or 139A led to an abundant accumulation of PrPSc in the 
tissue 5 weeks post inoculation, the extent of which was comparable to, or even 
higher than that seen in RML6-exposed slices (Fig. 12a, lane 11-13). Other less 
adapted scrapie strains 5193/1 and 5192/2 (brain homogenate from a terminally 
scrapie sick sheep from a flock in Colorado, USA passaged twice in tga20 or wt mice 
respectively) (C.J. Sigurdson et al, unpublished data) also replicated in tga20+/+ slices, 
but showed less abundant PrPSc accumulation after 5 weeks (Fig. 12b, lane 14-15).  
In addition, a murine adapted BSE strain reported not to replicate in N2A-PK1 cells, 
301C, replicated in tga20+/+ slices (Fig. 12b, lane 12). N2a-PK1 cells are also known 
to be resistant to an infection with the mouse adapted scrapie strain, ME7 (Klohn et 
al., 2003). In slices derived from tga20+/+ pups infected with ME7 (100 μg), a faint 
PrPSc signal could be found 5 weeks post inoculation (Fig. 12b, lane 13). We infected 
slices with an increased amount of ME7 (1 mg) and after 5 weeks a clear PrPSc signal 
was found in all ME7-treated tga20+/+ cultures (Figure 13c, lane 13-15), showing that 
POSCA exhibit a broad specificity.  
However, not all strains tested replicate in the POSCA after 5 weeks. Four murine-
adapted scrapie strains; 87A, 87V, 22F and 301V all failed to infect slice cultures 5 
week post inoculation (100 μg brain homogenate per 10 slices) (Figure 12, data not 
shown). These strains all exhibited long incubation times after intracerebral 
inoculation of 30 μl 10 % brain homogenate into C57BL/6 mice (>290 days, fig. 12d) 
(Carlson et al., 1994). In comparison, all strains that replicate in POSCA showed 
incubation times between 150-200 days (RML6, 79A, 139A, ME7, 5193/1 and 301C) 
(Fig. 12d). The only exception was 5192/2 that showed an incubation time of 270 
days (fig. 12d).  
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Figure 13. Versatile strain replication 
Strain selectivity of POSCA. (a-b) Cultures were prepared from 10-day old tga20+/+ and Prnpo/o pups, 
inoculated with 100 μg of infectious or mock brain homogenate and cultured for 35 days prior to 
harvesting the tissue. (a) Transmission of murine-adapted scrapie strains RML6, 139A, 79A and 
mock brain homogenate. Western blotting was performed on 20 μg protein digested with 25 μg/ml 
PK (+) or 10 μg non-digested protein (-) and detected with mouse anti-mouse PrPC IgG1 (POM-1). 
(b) Transmission of murine-adapted BSE 301C, murine adapted scrapie strains 5193/1, 5192/2, ME7, 
RML6 and mock brain homogenate. The RML6-infected slice culture sample was diluted 10-fold in 
mock brain homogenate prior to PK-digestion to decrease the PrPSc signal on the western blot. 
Western blotting was performed on 30 μg protein digested with 20 μg/ml PK (+) or 10 μg non-
digested protein (-) and detected with mouse anti-mouse PrPC IgG1 (POM-1). (c) Cultures were 
prepared from 10-day old tga20+/+ and Prnpo/o pups, inoculated with 0.1 and 1 mg of RML6, ME7 or 
mock brain homogenate and cultured for 35 days prior to harvesting the tissue. Western blotting was 
performed as indicated in (b). (d) Kaplan-Meyer plot comparing the incubation time until terminally 
disease of C57BL/6 mice inoculated intracerebrally with 30 μl, 10 % brain homogenate of various 
strains. Colored lines and symbols indicates strains that replicated in the POSCA and black lines and 
symbols indicate strains that did not. 
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This suggests a correlation between incubation times upon intracerebral inoculation 
into C57BL/6 mice and the ability of scrapie and BSE strains to replicate in the 
POSCA. 
We also tested a strain of mule-deer CWD from a Colorado flock adapted in tga20 
mice (Sigurdson et al., 2006). Tga20 mice inoculated intracerebrally with brain 
homogenate of a terminally sick mule-deer (30 μl, 10 % homogenate) came down 
with disease 400 days post inoculation upon 1st passage, 228 days post inoculation 
upon 2nd passage and 138 days post inoculation upon 4th passage. Despite the 2nd and 
4th passage showing short incubation times in vivo, murine-adapted CWD inoculums 
did not appear to replicate in tga20 slices 5 weeks post inoculation (100 μg brain 
homogenate per 10 slices, data not shown). All data are summarized in Table 2. 
 
Table 2. Synopsis of the various prion strains used for infection of POSCA slices 
 Original inocula were derived from scrapie affected sheep, BSE-affected cows, and CWD-affected 
deer. The columns display the number of mouse passages undergone by the inoculum ( > 4  passages 
are considered fully adapted), the genotype of the mice in which the inoculum was last passaged, and 
the average time until terminal disease (± SD) in the mice used to generate the inoculum. 
* Inoculum was generated from a single mouse 
** Only 3 out of 4 mice came down with scrapie 
*** No replication (-), weak replication (+), intermediate replication (++), strong replication (+++) as 
estimated by approximate density of PrPSc western blot signals. 
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Conditional microglia depletion using CD11b-HSVTK transgenic mice 
Conditional inhibition of microglia function in CD11b-HSVTK slices 
CD11b-HSVTK mice which allow for the conditional inhibition of microglia function 
in vivo and in vitro by treatment with the DNA-analogue ganciclovir (GCV) was 
previously generated  (Heppner et al., 2005). In brief, transgenic animals expressing 
the herpes simplex virus thymidine kinase (tk) enzyme under the Itgam promoter (the 
Figure 14. GCV-mediated inhibition of microglia activation in CD11b-HSVTK+ slices  
(a) LPS/IFN-γ-induced microglial activation in brain slices was accompanied by a pH change of cell 
culture supernatant within 48 h (yellowish color in wells C1–4, D1–3, A3–4, B3–4). Pretreatment of 
slice cultures derived from CD11b-HSVTK mice with GCV, inhibited such activation-associated pH 
changes (A1–2, B1–2). GCV-treatment abrogated the LPS/IFN-γ-induced (black bars) release of 
microglial TNF-α (b), nitrite (c) and MIP-1β (d) in tk+ OHSCs. White bars, non-stimulated OHSCs. 
Statistical significance was assessed by a one-way ANOVA test. ***: p < 0.001. 
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promoter driving CD11b-expression) was generated. Administration of GCV to 
transgenic CD11b-positive cells, leads to the phosphorylation and activation of the 
pro-drug by the tk enzyme. Subsequent incorporation of p-GCV into genomic and 
mitochondrial DNA causes death or cell cycle arrest of the cell (Rubsam et al., 1998; 
Heppner et al., 2005). I assessed the functional consequences of microglia paralysis in 
organotypic hippocampal slice cultures (OHSCs). OHSCs derived from CD11b-
HSVTK mice were stimulated with lipopolysaccharide (LPS) and interferon-gamma 
(IFN-γ), and microglia activation in the presence or absence of GCV (5 μg/ml) was 
determined. GCV treatment of stimulated OHSCs inhibited microglia activation-
dependent acidification of the cell culture supernatant (Figure 14b) and abrogated the 
release of nitrite, tumor necrosis factor (TNF) and macrophage-inflammatory protein-
1β (MIP-1β), suggesting a profound inhibition of microglia function (Figure 14c-e) 
(Heppner et al., 2005).  
Conditional depletion of microglia in organotypic CD11b-HSVTK slices 
I generated organotypic cerebellar slices derived from 10-day old CD11b-HSVTK 
mice, and added GCV to the medium. After 14 days, GCV treatment led to an almost 
complete loss of Isolectin-B4 (IB4)+ and CD68+ cells in CD11b-HSVTK+ (tk+) slices 
(Figure 15a-d). Remaining IB4+ cells appeared mostly fragmented (i.e. necrotic) or 
associated to IB4+ blood vessels (Figure 15a). Furthermore, time-lapse microscopy 
performed on IB4-labelled GCV-treated tk+ slices from 9-14 days in vitro confirm that 
microglia undergo an active form of cell death (See time-lapse video 1) and 
subsequently are taken up by neighboring (and still viable) microglia. Microglia 
depletion was quantified from images acquired by confocal laser scanning microscopy 
35-40 μm below the tissue surface (i.e. underneath the glial scar). tk+ slices showed a 
reduction in microglia of 97 %, 98 % and 99 % after 14, 28, and 42 days of GCV 
treatment, respectively (one-way ANOVA with Bonferroni’s multiple comparison 
test, p < 0.001, n = 4; Figure 15c). Very few if any microglia were found outside the 
tissue in treated CD11b-HSVTK+ slices (Figure 15d).  
Quantification of mRNA transcript levels by quantitative RT-PCR showed a 
significant (p < 0.001, n = 3) 98 % reduction in CD11b expression in TK+ slices 
treated with GCV for 14 days, whereas GFAP, MBP and neurofilament heavy-chain 
transcripts (markers for astrocytes, oligodendrocytes and neurons respectively) were 
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unaffected (one-way ANOVA with Bonferroni’s multiple comparison test, p > 0.05) 
(Figure 16a). Importantly, GCV treatment had no effect on wt slices (Figure 16a). 
GFAP protein expression increased over time and multiple lower-running isoforms 
could be observed after 7-21 days in culture (Figure 16). Depletion of microglia did 
not affect GFAP expression suggesting that the observed astrogliosis was independent 
of microglia activation. PrPC protein expression levels were unaffected in microglia-
depleted cultures (Figure 16b-c).  
 
 
 
Figure 15. Microglia depletion in organotypic slice cultures 
Cultures were prepared from 10-day old CD11b-HSVTK mice and cultured for 1, 14, 28 or 42 days, 
either untreated (-GCV) or in the presence of GCV (+GCV). Cultures were fixed in 2% PFA and 
stained with (a) IB4-Alexa488 or (b) rat α-CD68 IgG2a (only after 14 days in vitro). (c) Confocal 
images of IB4+ cells within the tissue were quantified. (d) Images were also acquired using a 
fluorescent microscope and IB4+ cells migrating out of the tissue was quantified (n = 3 replicas, each 
the average of 4 individual 40X images).  
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Specific conditional microglia depletion does not affect tissue viability 
Phosphorylated GCV released from dying microglia may be taken up by neighboring 
cells and cause toxicity (“bystander cell death”). The viability of CD11b-HSVTK 
slices treated with GCV for 14 days were assessed with respect to PI incorporation 
and DEVDase activity. Microglia-depleted slice cultures displayed a small, but 
significant increase in PI+ cells from approximately 1 % up to 2 % of the total area 
(One-way ANOVA with Bonferroni’s multiple comparison test, p < 0.001, n = 12) 
(Figure 17a). No difference in caspase activity was observed (n = 3, pools of 4 slices) 
(Figure 17a). Reconstitution of slices with intra-peritoneal wt macrophages partially 
rescued the GCV-induced increase in PI+ cells (Figure 17b).  
Figure 16. Specificity of microglia depletion in organotypic slice cultures 
(a) Cultures were prepared from 10-day old CD11b-HSVTK+ (tk+) and CD11b-HSVTK- (tk-) mice and 
cultured for 14 days with or without GCV. Total RNA was purified and cDNA was synthesized from 
1 μg total RNA. Real-time quantitative PCR was performed and fold regulation was calculated 
relative to untreated wt mice after normalization to the β-actin signal (n = 3). (b-c) Cultures were 
prepared from 10-day old tk+ and tk- mice and cultured for different days in vitro with or without 
GCV. Western blotting was performed on 10 μg protein and detected with (b) mouse anti-GFAP IgG1 
(Clone GA5) or (c) mouse anti-mouse PrPC IgG1 (POM-1). 
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I speculated that the increased number of PI+ cells might be due to dying/dead 
CD11b-HSVTK+ microglia. To test this, I performed dual-labelling of unfixed GCV-
treated CD11b-HSVTK slices with PI and IB4. In GCV-treated slices most PI+ cells 
were co-stained with IB4, indicating that the increase in PI+ cells was due to dead 
microglia (Figure 17c). Phosphorylated GCV released from dying cells cannot only 
cause bystander cell death, but also cell cycle arrest (Rubsam et al., 1998). To test for 
adverse GCV-mediated effects in the most sensitive way, I performed a BrdU-
incorporation experiment to label dividing cells. GCV-treatment of tk+ slices for 14 
days decrease greatly the number of BrdU+ cells in the tissue (Figure 18a). Co-
staining of slices with antibodies against BrdU and CD68 showed that GCV-treatment 
of tk+ slices abolished BrdU+/CD68+ cells as expected (Figure 18c). No significant 
effect was seen on the number of Brdu+/CD68- cells (BrdU+ cells characterized by a 
Figure 17. Minor impact of microglia depletion on tissue viability 
(a) Cultures were prepared from 10-day old tk+ and tk- mice and treated with GCV for 5 weeks, 
including a positive control of wt tissue treated with 5 μM staurosporine for 24 h and PI incorporation 
was measured (n = 12). Slices were harvested and caspase-3 enzymatic activity was measured and 
normalized to protein contents (n = 3 pools of 4 slices). (b) Slices were reconstituted with 250.000 
macrophages either by adding macrophages directly onto the tissue (+Ф) or separated by a membrane 
(sep.) (n = 12). (c) tk+ slices were treated with GCV for 10 days and living tissue were incubated with 
IB4 (green) and PI (red). Images were acquired on a wide-field microscope. Open arrows indicate 
IB4-/PI+ cells and closed arrows indicate IB4+/PI+ cells.  
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large nuclei) (Figure 18b-c). Also, no significant effect was seen by GCV-treatment of 
tk+ slices. Therefore, depletion of CD68+ cells is selective and transgene-dependent 
without significant bystander cell death.  
 
Figure 18. Microglia depletion does not affect proliferation of non-microglia cells 
(a) Cultures were prepared from 10-day old tk+ and tk- mice and treated with GCV. After 13 DIV 
BrdU incorporation was performed and the tissue was stained with rat α-bromodeoxyuridine IgG1. (b) 
Tissue was co-stained with α-bromodeoxyuridine (green) and α-CD68 IgG2a (red). Example of 
CD68+ (red) and BrdU+ (green) cells. Closed arrows represent CD68+/BrdU+ cells and open arrows 
represent BrdU+/CD68- cells. (c) CD68+/BrdU+ and CD68-/BrdU+ cells were counted (n = 6, each the 
average of 5 individual 40X images). Images analysis software analySIS© vs5.0 were used for all 
quantification purposes. Data is presented as the average of n replicas ± standard deviation (SD). 
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Impact of conditional microglia depletion on prion replication 
Microglia depletion leads to increased prions accumulation 
To address the contribution of microglia to prion formation/replication, I prepared 
slices from tga20TK CD11b-HSVTK- (tga20TK) and tga20TK CD11b-HSVTK+ pups 
(tga20TK+). Slices infected with RML6 (100 μg RML6, i.e. 2.7 log SCI50), were split 
into 2 pools and half the cultures were treated with GCV. After 30 days an equal 
amount of PrPSc was observed in all conditions except in GCV-treated tga20TK+ slices.  
Figure 19. Impact of microglia depletion on prion replication 
Cultures were prepared from 10-day old tga20TK or Prnpo/o mice either CD11b-HSVTK+ 
(tga20TK+ or Prnpo/o/TK+) or CD11b-HSVTK- (tga20TK) mice. After treatment with RML6 
(2.7 log SCI50), tga20TK and tga20TK+ slices were separated into 2 pools each and 1 insert 
out of each pool were treated with GCV. (a) Western blotting of 20 μg sample digested 
with PK (25 μg/ml) (b) or 10 μg sample undigested detected with mouse anti-mouse PrPC 
IgG1 (POM-1).  
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Microglia depletion resulted in a 5-fold increase in PK-resistant PrPSc (Figure 19a, 
lane 9). Since this increase was independent of PrPC expression (Figure 19b), 
microglia either directly affected the conversion of PrPC into PrPSc or – more likely – 
affected the half-life of PrPSc by phagocytosing and degrading prions. To test whether 
the observed increase in PrPSc was associated only with microglial expression of 
HSVTK I infected slices prepared from 10-day old GFAP-HSVTK mice that allows 
for conditional ablation of astrocytes (Bush et al., 1998). In contrast to CD11b-
HSVTK+ cultures, GCV-treatment of GFAP-HSVTK+ cultures had only a small or no 
effect on PrPSc levels (Figure 20a-b). Hence increased PrPSc levels are selectively 
associated with microglia depletion.  
Figure 20. Impact of astrocyte depletion on prion replication 
Cultures were prepared from 10-day old GFAP-HSVTK+ (gfapTK+), GFAP-HSVTK- (gfapTK) or 
Prnpo/o mice and treated with RML6 (2.7 log SCI50), gfapTK+ slices were separated into 2 pools and 1 
insert was treated with GCV. Western blotting was performed on (a) 20 μg sample digested with PK 
(25 μg/ml) (+) or (b) 10 μg undigested sample (-). 
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Macrophage reconstitution rescues effects caused by microglia depletion 
To further study whether the observed effect was due to GCV-mediated removal of 
microglia I performed a macrophage-rescue experiment. Tga20TK+ or Prnpo/o/TK+ slices 
were incubated with RML6 and treated with GCV to deplete microglia. Microglia-
depleted tissue was reconstituted with intra-peritoneal macrophages from Prnpo/o and 
Figure 21. Rescue of microglia depletion and impact on prion replication 
After treatment with RML6 (2.7 log SCI50), tga20TK+ and Prnpo/o/TK+ were separated into 4 pools each 
and 3 pools/condition were treated with GCV. 250.000 tga20 or Prnpo/o macrophages (tga20Ф and 
Prnpo/oФ respectively) were added to 2 GCV-treated cultures and after 30 days in vitro the tissue was 
harvested and analyzed. Western blotting was performed on (a) 20 μg sample digested with PK (25 
μg/ml) or (b) 10 μg undigested sample detected with mouse anti-mouse PrPC IgG1 (POM-1), (c) 
rabbit anti-human Iba1 (* indicate an unknown protein cross reacting with the Iba1 antibody as 
described by the supplier) or (d) mouse anti-GFAP IgG1 (Clone GA5). (e) Caspase-3 enzymatic 
activity was measured and normalized to protein contents. Data is presented as the average of 4 
biological replicas ± standard deviation (SD). One-way ANOVA with Bonferroni post-test for 
selected pairs of columns was used for statistical analysis (n.s. = p > 0.05).  
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tga20+/+ mice respectively. After microglia-depletion a clear increase in PrPSc was 
observed as expected (Figure 21a, lane 6-7). This increase in PrPSc could be almost 
completely rescued by reconstituting the tissue with macrophages, irrespectively of 
whether the macrophages expressed PrPC (Figure 21a, lane 8-9). Microglia 
depletion/reconstitution was verified by analyzing the expression levels of the 
macrophage marker Iba1 (Figure 21c). PrPC levels were equal in all samples (Figure 
21b) and no differences in caspase activity (Figure 21e) or GFAP expression (Figure 
21d) were observed in either of the prion infected tissues.  
 
Microglia depletion leads to a significant increase in prion infectivity 
Next, we used SCEPA to analyze tga20TK+ samples, untreated or treated with GCV 
for 30 days from 3 independent biological experiments performed on different days 
(Figure 22a). Microglia-depleted cultures showed a significant 14.5 ± 13.2 fold 
increase over non-depleted cultures in their prion titers (2-tailed paired student T-test, 
p = 0.458, n = 3), which corresponds well to the difference observed by western blot 
analysis of the samples analysis of microglia-depleted samples (a 9 ± 11.8 fold 
increase over non-depleted slices, n = 6) (Figure 22a-b, data not shown). Despite a 
high inter-experimental variance, all 6 independent replicas displayed a clear increase 
in PrPSc accumulation after microglia-depletion (a 2-33 fold increase). No residual 
inoculum was observed in Prnpo/o/TK culture irrespectively of microglia status (Figure 
22b). These result confirm that microglia regulate both PrPSc and prion formation in a 
negative fashion.  
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Figure 22. Microglia depletion leads to accumulation of prion infectivity 
Homogenates of tga20TK+ or Prnpo/o/TK+ slices infected with RML6 (2.7 log SCI50) for 5 weeks either 
in the absence (-GCV) or presence of GCV (+GCV) were transmitted into the scrapie cell assay in 
endpoint format (SCEPA). (a) Micrograph of a representative plate containing one -GCV and one 
+GCV sample. (b) 3 independent biological replicas of tga20TK+ and single replicas of Prnpo/o/TK+ 
slices or RML6 were analyzed in 10-fold dilution steps from 100 μg/ml – 1 ng/ml using 6-12 replica 
wells per dilution (300 μl/well). 
 _________________________________________________________________________________ 
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Microglia depletion leads to an increased susceptibility to a prion infection 
Microglia-depleted tissue accumulates prions to a higher degree, begetting the 
question whether GCV-treated tk+ slices would be more sensitive to a prion infection.  
I therefore performed an end-point titration experiment with RML6 on tga20TK+ 
slices. Tga20TK+ slices were infected with various concentrations of RML6 and 
separated into 2 pools. One pool was left untreated and the other was treated with 
GCV. After 5 weeks in vitro, PK-resistant material was observed in microglia-
depleted tissue at a 10-fold lower RML6-dilution (-0.3 log SCI50), showing that 
microglia-depleted tissue indeed is more sensitive to a prion infection (Figure 23a-b).  
 
 
Figure 23. Impact of microglia on tissue susceptibility to a prion infection 
Cultures were prepared from 10-day old tga20TK+ or Prnpo/o/TK+ mice and treated with RML6 in 10 
fold dilution steps from 1.7 to -1.3 log SCI50. Each samples was divided in 2 pools. One pool was 
treated with GCV and one pool was left untreated. The tissue was harvested after 35 days in vitro. (a) 
Western blotting of 20 μg sample digested with PK (25 μg/ml) or (b) 10 μg sample undigested 
detected with mouse anti-PrPC IgG1 (POM-1). 
_________________________________________________________________________________ 
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DISCUSSON 
POSCA 
In order to study the role of microglia in prion disease, I have developed the POSCA, 
a novel assay system which allows for prion infectivity determination and for 
studying prion replication ex vivo in a complex cellular environment. I have evaluated 
the operating characteristics of the POSCA against the 2 most commonly used prion 
titration assays: the SCEPA (Klohn et al., 2003) and the mouse endpoint bioassay 
(Fischer et al., 1996).  
The SCEPA is a cell-culture based prion replication assay using a neuroblastoma 
subclone, N2a-PK1. Alternative primary cell culture assays have recently been 
reported. Primary cultures of neurons, astrocytes, neural stem cells and neurospheres 
has been shown to be infectible in vitro (Cronier et al, 2004; Giri et al., 2006; 
Milhavet et al., 2006). However, in these culture systems residual prion inoculum 
persisted in Prnp-deficient cultures after 24-28 days. SCEPA measured approximately 
8 log LD50 per g brain material and the neurosphere assay measured approximately 5 
log LD50/g (Klohn et al., 2003; Giri et al., 2006). The POSCA assay measures 
approximately 6.9 LD50/g. When I depleted microglia I could even detect a 10-fold 
lower dilution of RML6, therefore approaching the sensitivity of the SCEPA. 
Importantly, residual inoculum does not constitute a problem for the POSCA.  
As a research tool, cell line based assays have the disadvantage that there is a limited 
number of cell lines available, especially PrP-deficient cell lines, making it difficult to 
control experiments stringently. Ex vivo organotypic brain slice cultures can be 
prepared from mice of any desired genotype and the tissue can easily be manipulated. 
This gives us a flexible and robust experimental system to study prion infection in. 
Importantly, cells retain the cellular connections of a normal brain, allowing for the 
study of the role of different cell types in prion replication and pathogenesis.  
Many cell lines also show a high selectivity in which prion strain the cells can 
replicate. As compared to tumor cell lines, certain transgenic mouse lines are more 
‘promiscuous’ in their inoculum compatibility. In contrast to the SCEPA, the POSCA 
can avail itself of the large repository of genetically modified mouse lines susceptible 
to prions of human, bovine, ovine, and cervid origin. This can allow us to study the 
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phenomenon strain adaptation and strain propagation (Weissmann, 2004). This can be 
done in a well-controlled fashion over multiple passages in a relative short period of 
time. I have successfully infected slice cultures using inoculum passaged in our slice 
cultures (data not shown). 
Compared to in vivo models, the slice culture system has a very short incubation time. 
I observe prion replication already after 20 days in tga20TK cultures (10-3 RML6). 
Tga20 mice inoculated intra-cerebrally with a high dose of RML6 take 60-150 days to 
come down with clinical disease (Klohn et al., 2003). Furthermore, I observe prion 
replication in Prnp+/o slices after 35 days. In vivo, Prnp+/o mice have an incubation 
time of 225-300 days before coming down with clinical disease after intra-cerebral 
inoculation (Büeler et al., 1993). The reason why I see such a rapid replication in our 
in vitro system is unknown, but useful none-the-less. An additional feature of our 
model is that prions are replicated to a very high extend. I observed similar amounts 
of prions in homogenates from prion infected slice cultures and in brains of terminally 
sick mice, both by PK western blotting and by transmission into the SCEPA.   
Microglia involvement in prion disease 
Microglia activation is an early and extensive hallmark of most prion diseases. 
Numerous studies show that microglia can release inflammatory and neurotoxic 
factors typically associated with neurodegenerative diseases (Dandoy-Dron et al., 
1998; Baker and Manuelidis, 2003; Baker et al., 2004). It has even been claimed that 
prion neurotoxicity is crucially mediated by microglia (Brown et al., 1996; Kercher et 
al., 2007). Mice devoid of a microglia-borne factor, Interleukin-1 were reported to 
experience a modest increase in survival time as compared to wt mice, which suggests 
and indirect link between microglia-mediated inflammation and neurodegeneration 
(Schultz et al., 2004).  
The suggestion that microglia could play a role in prion turnover stem from the 
observation that microglia often are associated with prion plaques and that infectivity 
can be recovered from microglia purified from terminally sick mice (Manuelidis et al., 
1997; Andreoletti et al., 2002; Baker et al., 2002). It was hypothesized that microglia 
acts as a carrier of prions within the brain and thus could play a role in the 
dissemination of prions within the CNS (Baker et al., 2002). In mice reconstituted 
with eGFP-labelled bone marrow, microglia turnover and CNS engraftment by 
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peripheral monocytes was increased dramatically upon prion infection. This suggested 
that wt monocytes engrafting the brain of Prnpo/o mice are neither able to transport 
prions to the CNS nor to replicate prions (Priller et al., 2006). This is in agreement 
with observations that other peripheral macrophage populations are capable of 
reducing prion infectivity in vitro and PrPSc accumulation in the spleen in vivo (Carp 
and Callahan, 1982; Michel et al., 1987; Beringue et al., 2000).  
Selective manipulation of microglia in vivo is hampered by their similarities to 
macrophages. Here I used CD11b-HSVTK mice (Heppner et al., 2005) for 
pharmacogenetic ablation of microglia. I found that microglia can be completely 
ablated from cerebellar slice cultures derived from CD11b-HSVTK+ mice, and this 
ablation has no obvious implications for the viability of other cell populations. I then 
show that microglia removal dramatically unleashes prion replication in organotypic 
slices. This points to a role for microglia in containment of prion infections. Microglia 
may exert this role by phagocytosing and degrading prions in situ (Carp and Callahan, 
1982; Michel et al., 1987; Beringue et al., 2000; Priller et al., 2006), This may explain 
the presence of prions in microglia acutely isolated from scrapie-sick mice (Baker et 
al., 2002) despite the inability of microglia to replicate prions (Priller et al., 2006).  
There may be eminently practical ramifications to the phenomena described above. 
One ID50 unit of prions measured upon intracerebral challenge has been reported to be 
equivalent to 104-105 PrP molecules (McKinley et al., 1983). This is in sharp contrast 
to many viral diseases in which 1-10 particles are equivalent to 1 ID50, and has even 
been taken to cast doubts on the identity of the prion with PrPSc (Manuelidis et al., 
1987). The priolytic activity of microglia uncovered in the present study may 
contribute to increasing the minimal amount of PrPSc needed to infect individual 
organisms. One hypothesis for the etiology of sporadic CJD states that PrPSc 
formation could be a stochastic event, which under normal circumstances are cleared 
from the brain. Changes compromising the brains capacity to clear PrPSc, such as the 
loss of microglia seen in other neurodegenerative disease (Ma et al., 2003) could then 
lead to an uncontrolled replication/deposition of PrPSc and neurodegeneration (Safar 
et al., 2005). We show in the current study, that microglia constitute exactly such a 
brain-specific clearing mechanism. As it has previously been shown that aging 
microglia show a decrease capacity to phagocytose amyloids (Floden et al., 2006), 
one might speculate whether microglia dysfunction associated with aging could be an 
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underlying cause for sporadic CJD. By extension, one might also speculate that 
medical conditions and iatrogenic interventions which affect the function of microglia 
may heighten the susceptibility to prion infections. 
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OUTLOOK 
POSCA 
Many cell lines show a high selectivity in which prion strain the cells can replicate. 
Researchers in many different laboratories world-wide are currently working with 
primary strains of scrapie for which there is no compatible cell-based prion assay. 
Recently, it was reported that bank voles (Clethrionomys glareolus), a wild rodent 
species, are susceptible to prions from a range of sources including various strains of 
scrapie, BSE and CJD (Nonno et al., 2006). Transgenic mice expressing the bank vole 
prion protein was generated in the lab of Juan M. Torres (unpublished data). We have 
received these mice and we are hoping to establish a slice culture based assay of 
broad specificity based on slices prepared from ‘bank volized’ mice. 
Microglia in prion diseases 
The role of microglia in neurodegenerative diseases is multi-faceted. In Alzheimer’s 
disease microglia and infiltrating monocytes appear to play a neuroprotective role by 
antagonizing amyloid deposition (Simard et al., 2006), while at the same time 
contribute to pathology via the production of neurodegenerative factors such as 
reactive oxygen species, cytokines and complement factors (Heneka et al., 2007). 
Overall, it would appear that microglia play a neuroprotective role in Alzheimer’s 
disease (Khoury et al., 2007) and therefore pharmacological intervention should focus 
on shaping, not blocking, a disease-associated microglia response. Indeed it has been 
shown in several independent studies that anti-inflammatory drugs modulating 
microglia function has pharmacological potential, making microglia a potentially 
important drug target in neurodegenerative protein-misfolding diseases (McGeer et 
al., 2006).  
Analogues to what is seen in Alzheimer’s disease, I observe that microglia 
antagonizes prion formation in organotypic brain slices. Our results indicate a 
protective role for microglia in prion disease. However, mRNA profiles of microglia 
purified  from prion-infected animals suggests a pro-inflammatory and potentially 
neurotoxic function of microglia (Almond et al., 1995; Dandoy-Dron et al., 1998; 
Baker et al., 2002; Baker and Manuelidis, 2003; Baker et al., 2004). A possible 
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neurodegenerative function of microglia was not explored in the POSCA in detail. I 
am currently investigating whether longer incubation times will allow us to observe 
prion-induced neurodegeneration in POSCA. If that is so, I plan to explore the 
contribution of microglia to prion-induced cell death. Furthermore, I plan to explore 
the inflammatory response of microglia in prion-infected slices by quantitative PCR.  
In addition, I am currently evaluating if pharmacological intervention or treatment 
with cellular factors can stimulate or inhibit prion removal. In short, prion-infected 
cultures are treated with recombinant cytokines and pharmacological agents that have 
been reported to affect microglia function. Factors that affect prion replication will be 
screened in microglia-depleted tissue to confirm whether the prion-modulatory effect 
is microglia-dependent. 
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PART II 
_________________________________ 
 
Part II of my thesis consists exclusively of unpublished data.  
INTRODUCTION 
Prion replication in mono-cultures. 
In order to understand prion replication and prion-induced pathology, a simplified cell 
culture system can be an important tool to dissect the molecular mechanisms behind 
it. It has been known for more than 35 years that prions can survive in cell culture. 
Explant cultures from chimpanzees experimentally infected with Kuru, a human 
iatrogenic form of CJD, persisted in harboring infectivity for up to 250 days in vitro 
(Gajdusek et al., 1972). Whether infectivity was amplified in vitro or if infectivity 
only persisted was not investigated. In the above mentioned studies cultures were 
prepared from monkey infected more than a year earlier. An easier approach to study 
prion replication in an in vitro system would be to prepare primary cultures of 
uninfected neonatal tissue or use cell lines and infect the cultures ex vivo. 
Unfortunately, this approach carries some drawbacks. The main concerns/obstacles 
for studying prion replication in vitro (as well as in vivo) is persistence of the prion 
inoculum. Primary cells and cell lines are cultured on coated plastic dishes that will 
bind proteins, including PrPSc from the inoculum. It is currently impossible to clearly 
distinguish between PrPSc from the original input material and de novo synthesized 
prions.  
This obstacle can be overcome by using cell lines or cultures of primary cells that 
undergo mitosis at a rapid rate and can be serially passaged. The scrapie cell assay 
technique is based on the fact that cells can be passaged repeatedly after the initial 
inoculation, usually by splitting the cells 1:3, 3 times, followed by splits of 1:10, 3 
times. This procedure dilutes out the original inoculum to an extend where it is no 
longer detectable and therefore all the PrPSc that can be detected must come from de 
novo replication of prions. This approach is the basis for the SCEPA (Klohn et al., 
2003) and has been shown to work well for prion-infection of a number of cell lines 
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and for mouse neurospheres (Giri et al., 2006). The process is relatively labor-
intensive and time consuming, but it can be automated. Another alternative is to use 
chronically infected cell lines (Solassol et al., 2003).  
For primary neural cultures that are either post-mitotic (neurons) or dividing very 
slowly (astrocytes, microglia, oligodendrocytes) residual inoculum constitutes a major 
issue. Various approaches has been used to infect differentiated neural cells. 
Monolayers of differentiated neural stem cells was reported to be susceptible to prions 
(Milhavet et al., 2006). To avoid residual inoculum, the input material was solubilized 
using high detergent concentration and both inoculum and detergents were added to 
the cells. Other reports ignored the issue altogether and reported that the PrPSc signal 
increased over time above the signal of Prnpo/o cells treated with the same amount of 
input material (Cronier et al., 2004; Cronier et al., 2007). Despite the slightly crude 
method of the study, the authors reported that cerebellar granule neurons and 
astrocytes can replicate prions in vitro. Currently, there is no easy or robust method to 
infect primary neural cultures. Recently, another exciting approach on how to 
distinguish between inoculum and de novo synthesis was reported (Vorberg et al., 
2004). The authors infected cells expressing a tagged version of the prion protein. 
PrPSc was subsequently detected with a tag-specific antibody (that did not recognize 
PrPC in the inoculum). This method requires that the tag becomes a part of the PK-
resistant portion of the prion protein upon prion replication (Vorberg et al., 2004). 
Unfortunately, it appears that tagging the prion protein is a very efficient method to 
inhibit or prevent the conversion of PrPC to PrPSc in vivo (Barmada and Harris, 2005) 
and to date no transgenic animals carrying an easily convertible tag has been reported 
in the literature. 
Prion protein deletion mutants 
The normal function of the cellular prion protein and the cause of the neurological 
disease which develops during the conversion of PrPC to PrPSc remain poorly 
understood. Mice expressing a deletion in the prion protein between residues 32-134 
(ΔF) (Shmerling et al., 1998; Radovanovic et al., 2005) or mice with smaller C-
terminal deletions lacking residues 93-134 (ΔHC) (Baumann et al., 2007) or 105-125 
(Li A, 2007) develops neurological phenotypes and die at a very young age. 
Histological and biochemical analysis of the mice show that terminally sick ΔF and 
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ΔHC mice suffers from a white matter pathology involving progressive 
demyelination, synaptic dysfunction, and axonal degeneration. For ΔF mice and for 
mouse lines expressing low amounts of ΔHC, this phenotype is apparent only in the 
absence of full-length PrPC expression (on a Prnpo/o background) (Shmerling et al., 
1998). High expressing mouse lines of ΔHC mice develops pathology even on a 
Prnp+/o background, but not on a Prnp+/+ background showing that PrPC rescues the 
phenotype induced by the deletion mutants in a concentration dependent fashion 
(Baumann et al., 2007). Whether toxicity stems from a loss of function or a gain of 
function induced by the mutants is uncertain. Aged, 60 weeks old, Prnpo/o mice do 
show a similar, but much less severe white matter pathology and axonal loss (Nishida 
et al., 1999). It is feasible that PrPC is part of a complex important for myelin 
maintenance and that pathology develops in ΔHC mice due to an accelerated loss-of-
function caused by interference with this complex (Baumann et al., 2007). 
In contrast, mice expressing a smaller N-terminal deleted prion protein lacking 
residues 69-84 (ΔA), 32-80 (ΔB) (Fischer et al., 1996) or 32-93 (ΔC) (Flechsig et al., 
2000) do not develop any obvious signs of neurodegeneration. Despite lacking parts 
or all of the octa-peptide repeat region, both ΔB and ΔC mice replicate prions, albeit 
less efficient than mice expressing the full-length prion protein (Fischer et al., 1996; 
Flechsig et al., 2000). Prion-infected ΔC mice (C4/C4 line) succumbs to prion 
disease, showing signs reminiscent of prion-infected mice expressing full-length PrPC. 
Surprisingly, these prion-infected mice do not show any obvious scrapie-associated 
histopathological changes in the brain. In the spinal chord, pathological changes 
(increased GFAP expression and loss of motor neurons) are similar to what is seen in 
scrapie infected wild-type mice. Infectivity can be recovered from the brain (30-fold 
less than wild-type mice) and spinal chord (equal to wild-type mice) of terminally 
sick RML-infected C4/C4 mice. Homogenates of ΔC(RML) (RML passaged in 
C4/C4 mice) re-transmitted into mice expressing full-length PrP, causes prion-
replication and pathology to the same extend as RML (Flechsig et al., 2000).  
Outline of this work 
The focus of the current study was to develop tools to study prion replication in vitro, 
specifically to overcome the problem of distinguishing between inoculum (input) and 
de novo synthesized PrPSc (output). I used ΔC(RML) (lacking the octa-peptide repeat 
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region) as inoculum to infect slices prepared from mice expressing full-length PrPC. 
PrPSc synthesized from PrPC contained the octa-peptide repeat region, which was 
absent in the inoculum. I used an antibody specific for the octa-peptide repeat region 
to detect PK-resistant PrP and this antibody selectively recognized newly synthesized 
PrPSc. This technique allows us to specifically observe prions replication in vitro and 
in vivo in wild type and transgenic mice. I used the technique to characterize which 
CNS-specific cell types replicate prion in vitro. I found that primary cultures of 
cerebellar granule neurons and astrocytes replication prions. In contrast, I could find 
no evidence suggesting that microglia replicate prions. A further characterization of 
which CNS and PNS-derived cells replicate prions is still in progress. 
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RESULTS 
‘Invisible inoculum’ 
In order to establish a method for the selective detection of prion replication, I took 
advantage of the work of Flechsig and Weissmann showing that homogenates of prion 
inoculated ΔC mice (C4/C4) inoculated with the RML strain are infectious to mice 
Figure 24. Parameters necessary for selectively detecting de novo prion replication in vitro 
(a) The POM-12 monoclonal antibody recognizes an epitope in the PrPC-octarepeat-region, which 
has been deleted in the PrP-deletion mutant mouse ΔC (C4/C4). POM-1 recognizes alpha-helix one 
on both PrPC and ΔC. (b) PNGase treatment of wt mock brain homogenates, RML6, brain 
homogenates from ΔC mice (ΔC(mock)) or RML inoculated terminally sick ΔC mice (ΔC(RML)). 
(c-d) 20 μg RML6 was digested with 25 μg/ml PK at various pHs. Western blots were detected 
using mouse anti-PrPC IgG1 (c) POM-1 or (d) POM-12, showing that pH 6-7 is optimal for 
detection of PK-resistant PrPSc with POM-12. (e) Scheme depicting set-up for distinguishing 
between input and output material. ΔC(RML) lacking the POM-12 epitope is used to infect cells 
expressing full-length PrPC. PK-resistant material is detected using POM-12 that should only 
recognize host-derived PrPSc, not ΔC(RML). 
________________________________________________________________________________ 
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expressing full-length PrP (tga20+/+) (Flechsig et al., 2000). ΔC(RML) homogenates 
contain high levels of PrPSc, generated from the PrP deletion-mutant, ΔC, devoid of 
the octa-peptide repeat region (Figure 24a). Furthermore, I took advantage of a 
previous observation, indicating that 2 octa-repeat region specific anti-PrP antibodies 
generated in the Aguzzi lab (POM-2 and POM-12), recognize PK-resistant PrPSc 
(Polymenidou et al., 2005). I hypothesized that if I use ΔC(RML) to infect cells 
expressing full-length PrP, POM2 or POM12 would selectively recognize newly 
synthesized PrPSc (Figure 24a). ΔC(RML) was obtained from Eckhard Flechsig and 
analyzed by western blotting after treatment with PNGase (a deglycosylation enzyme 
that removes N-linked sugar moieties). After treatment with PNGase both ΔC(RML) 
and ΔC(Mock) (homogenates of an uninfected C4/C4 mouse) migrated faster than 
homogenates of an RML-infect or uninfected wt mice by SDS-PAGE (Figure 24b). 
These results confirmed that the ΔC samples only contain truncated-PrP as could be 
expected. I observed that the pH of the lysis buffer greatly affected detection of PrPSc 
with POM-12 (Figure 24d) and to some extend also with POM-1 (Figure 24c). 
Therefore, 100 mM Tris-HCL (pH 7.0) was added to the lysis buffer. Since the POM-
12 epitope was absent in the inoculum, I predicted that we would not detect any 
inoculum using POM-12. I therefore skipped the washing steps normally used for 
removing residual inoculum. The tissue was incubated as free-floating sections in 
inoculum-containing buffer and after 1 h at 4 °C, the tissue was transferred to the cell 
culture membrane (Figure 24e). 
Slices generated from tga20+/+ or Prnpo/o pups were treated with RML6, ΔC(RML) 
and ΔC(Mock) (100 μg per 10 slices). After 5 weeks in vitro, slices were harvested 
and both slices and inoculum was analyzed by PK-western blot (Figure 25a-b). 
Undigested RML6, ΔC(RML) and ΔC(Mock) inoculum (10 μg per blot) were 
analyzed by western blot and detected with POM-1, showing faster running patterns 
for all ΔC-samples, indicating a smaller molecular weight as expected (Figure 25a, 
lane 2-4). After digestion with PK, ΔC(RML) showed a much lower PrPSc signal 
compared to RML6, but a clear PK-resistant PrP-signal was detected none-the-less 
(Figure 25a, lane 5-7). Tga20+/+ slices treated with ΔC(RML) showed abundant PrPSc, 
whereas mock and Prnpo/o slices did not show any PK-resistant material 5 weeks post-
inoculation, confirming that  ΔC(RML) could replicate in tga20-derived slices (Figure 
25a, lane 8-10).  
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The same samples loaded onto a replica blot were analyzed using POM-12. As 
predicted, POM-12 clearly detected undigested and PK-digested RML6, but no signal 
was detected in lanes loaded with ΔC inoculum (Figure 25b, lane 2-7). A PK-sensitive 
37 kDa band was detect in RML6 and ΔC samples with POM-12, but this band is also 
present in Prnpo/o samples, indicating that POM-12 cross reacts with a non-PrP 
moiety (Figure 25b, lane 2-4, data not shown). A strong PrPSc signal was detected in 
tga20+/+ slices infected with ΔC(RML), showing that POM-12 only recognized newly 
generated PrPSc, in essence rendering the inoculum ‘invisible’ (Figure 25b, lane 8-10). 
Figure 25. Selective detection of de novo prion replication 
Cultures from tga20+/+ and Prnpo/o mice were inoculated with ΔC(RML), ΔC(Mock), RML6 or 
mock brain homogenate and cultured for 35 days prior to harvesting the tissue in pH 7.0 lysis 
buffer. Western blots of PK-digested inoculum and slice culture homogenates were detected using 
mouse anti-PrPC IgG1 (a) POM-1 or (b) POM-12.  
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Prions replication in primary CNS cultures 
Cerebellar Granule Cells 
Next, I proceeded to test which CNS-derived cell populations can be infected with 
prions in vitro. Cerebellar granule cells (CGCs) make up more than 95 % of the total 
number of cells in the cerebellum and are easy to culture staying viable for up to 4 
weeks in vitro. CGCs were prepared according to established methods (Leist et al., 
1997). Since I previously observed that prion replication is more efficient in ex vivo 
cultures of cerebellar tissue in the absence of microglia, I first established the 
parameters for microglia depletion in CGC cultures using the CD11b-HSVTK mice 
(Figure 26 and 27). Cultures were prepared, treated with GCV (5 μg/ml) for 10 days, 
fixed and stained for various cell populations. As observed in organotypic slice 
cultures, GCV-mediated microglia removal was transgene-dependent (Figure 26a), 
without any overt effects on the neuronal axonal network of the CGCs (Figure 26b).  
CGC-cultures contained about 5 % astrocytes, which showed a close physical 
interaction with cerebellar granule neurons (i.e. all neuronal cell bodies appeared to be 
in direct contact with astrocyte projections). Microglia depletion did not affect the 
Figure 26. Microglia depletion in cerebellar granule cell cultures 
Cerebellar granule cells were prepared from 7-day old CD11b-HSVTK- (tk-) and CD11b-HSVTK+ 
(tk+) mice and cultured for 10 days, either untreated (-GCV) or in the presence of GCV (+GCV). (a) 
Cultures were fixed in 2 % PFA and co-stained with IB4-Alexa488 (green), mouse α-βIII-tubulin IgG1 
(red) and dapi (blue) (b) Phase contrast images of the regions depicted in (a). 
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number or the morphology of astrocytes (Figure 27a). Within 10 days of GCV-
treatment tk+ microglia were completely abolished from the culture (Figure 27b). The 
few microglia that remained showed a condensed cytoplasm and appeared dead 
(Figure 28a). GCV treatment and microglia depletion also did not affect the viability 
Figure 27. Microglia depletion in cerebellar granule cell cultures 
Cerebellar granule cells were prepared from 7-day old CD11b-HSVTK- (tk-) and CD11b-HSVTK+ 
(tk+) mice and cultured for 10 days, either untreated (-GCV) or in the presence of GCV (+GCV). (a) 
Overlay of phase contrast images (green), and cells stained with dapi (blue), and rabbit α-GFAP 
polyclonal antibody (red). (b) Images from Figure 26 (a) were quantified (n = 6 biological replicas, 
each the added value of 5 images (20X)). Non-fixed cultures were co-stained with Dapi and PI. (c) 
Representative images of PI-positive tk+ +GCV cultures. (d) Images were quantified (n = 6 
biological replicas, each the average value of 4 images (20X)). 
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of the cultures as measured by PI-incorporation (Figure 27c-d). 
I initially tested 3 different infection regiments to prion infect CGCs. I prepared CGC 
cultures from tga20TK mice and added GCV to the cultures. Cultures were either 
treated with 2.5 μg or 25 μg ΔC(RML) inoculum (in 250 μl medium) in the presence 
of 10 % FCS for 24 h  before changing the medium to fresh, serum free medium. 
After the medium change 25 μg inoculum was added back to 1 of the cultures. 
Cultures were harvested 3 and 4 weeks post-inoculation and analyzed by PK-western 
blot. In all conditions a clear, albeit variable PrPSc signal was observed after 3 and 4 
weeks, regardless of treatment regiment (Figure 28, lane 10-15). No PrPSc was found 
in mock treated tga20TK or in ΔC(RML) treated Prnpo/o samples (Figure 28, lane 4, 7-
9). 
 
 
Figure 28. Prion infection of cerebellar granule cell cultures 
Cerebellar granule cells were prepared from 7-day old tga20TK mice and cultured in the presence of 
GCV. Cultures were inoculated with different concentrations of ΔC(RML) or ΔC(Mock) for 24 h 
after which the medium was exchanged to serum free medium. In some conditions the inoculum 
was re-added after the medium exchange After 3 or 4 weeks in vitro, cells were harvested, PK-
digested using 5 μg/ml PK to digest 8 μg protein and samples were analyzed by western blotting. 
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Microglia 
In a complex cellular environment the depletion of microglia led to an increase in 
prion replication (see PART I). This suggests that microglia are capable of removing 
prion, but it does not per se rule out that microglia also are capable of replicating 
prions. Indeed it was reported that immortalized microglia from PrP-overexpressing 
mice can be prion infected (Iwamaru et al., 2007). I prepared mixed glia cultures from 
tga20+/+ and Prnpo/oTK mice and after 14 days, microglia were shaken off from the 
tga20+/+ cultures and co-cultured with a feederlayer of Prnpo/oTK astrocytes. The 
cultures were treated with 10 mg ΔC(RML) or ΔC(Mock) (in 10 ml, 75 cm2 flask) 
and treated with GCV for 5 weeks. After 5 weeks, the tga20+/+ microglia were 
recovered and compared to microglia recovered from Prnpo/o/TK cultures treated with 
ΔC(RML). A very weak PrPC signal was detected in tga20 microglia, but no PK-
Figure 29. Prion infection of 
microglia 
(a) Microglia were purified from 14-
day old mixed glia cultures 
(prepared from 1-day old tga20+/+ 
pups). Cells were seeded on a feeder 
layer of Prnpo/o/TK+ astrocytes and 
inoculated with ΔC(RML) or 
ΔC(Mock) for 72 h. Cells were 
cultured in the presence of GCV for 
5 weeks. Microglia was shaken off 
the feeder-layer and purified by 
differential adherence by letting the 
cells adhere to a plastic surface for 
45 min (not allowing time enough 
for astrocytes to attach). (b) To 
qualitatively compare the PrPC 
expression level of neurons to 
microglia, cell homogenate from 
Figure 26 and from (a) was loaded 
on the same blot. Microglia show a 
dramatically lower PrPC expression 
as compared to neurons. 
____________________________ 
a 
b 
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resistant material was found in any of the tested conditions, suggesting that microglia 
do not support prion replication (Figure 29a). I compared the expression level of PrPC 
in CGCs and in microglia. Microglia expressed almost no PrP to as compared to 
cerebellar granule neurons, well in line with their apparent inability to replicate prions 
(Figure 29b).  
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Astrocytes 
Finally, I tested whether microglia-depleted astrocyte cultures could be prion infected. 
Once again I verified that I can obtain an efficient microglia depletion in mixed glia 
cultures prepared from CD11b-HSVTK mice. Tk+ and wt cultures were prepared and 
Figure 30. Microglia depletion in mixed 
glia cultures 
Mixed glia cultures were prepared from 1-
day old CD11b-HSVTK+ pups and cultured 
for 10 days, either untreated (-GCV) or in 
the presence of GCV (+GCV). (a) Cultures 
were fixed in 2 % PFA and co-stained with 
IB4-Alexa488 (yellow) and dapi (blue). (b) 
Images were quantified (n = 6 biological 
replicas, each the average value of 4 images 
(20X)).  
_________________________________ 
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treated with GCV (5 μg/ml) for 10 days. Once again I observed an efficient, 
transgene-dependent depletion of microglia from the cultures (Figure 30a, b). In the 
same experiment I compared GCV-mediated microglia depletion to depletion with 
Clodronate-liposomes, a gliotoxin known to deplete microglia (Markovic et al., 2005). 
Although Clodronate-liposomes did lead to a decrease in the microglia numbers, the 
depletion was incomplete and induced a certain degree of toxicity to astrocytes (figure 
30b, data not shown).  
CD11b-HSVTK+ astrocytes expressing wild type levels of PrPC were treated with 
ΔC(RML) (2.5 μg RML6, in 250 μl) and GCV. 5 weeks post-inoculation ΔC(RML) 
treated CD11b-HSVTK astrocytes showed a faint PrPSc signal in 2 out of 3 replicas, 
suggesting that astrocytes can replicate prions (Figure 31, lane 13-15). In ΔC 
ΔC(mock) treated CD11b-HSVTK+ astrocytes and in ΔC(RML) treated Prnpo/o 
cultures, no PK-resistant material was detected (Figure 31, lane 7-12). 
Figure 31. Prion infection of astrocyte cultures 
Mixed glia cultures were prepared from 1-day old CD11b-HSVTK+ and Prnpo/o pups and cultured 
for 10 days, in the presence of GCV. Cells were inoculated with ΔC(RML) or ΔC(Mock) for 72 h. 
After 5 weeks the cells were harvested, PK-digested using 5 μg/ml PK to digest 8 μg protein and 
samples were analyzed by western blotting. 
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DISCUSSION 
‘Invisible inoculum’ 
In order to study prion replication in non-dividing cells I have generated a new 
method that allows us to identify newly generated PrPSc in a selective manner. I am  
not the first group to come up with a technical setup that allows the for study of de 
novo prion replication in a stringent fashion (Vorberg et al., 1999). But whereas the 
previously reported method relied upon using a normal prion inoculum to infect cells 
expressing a tagged-PrP molecule, our method is the diametrical opposite. I use a 
specially modified inoculum to infect normal cells. The advantage of our method is 
obvious. The method devised by Vorberg et al. requires that cells that are to be 
infected express a tagged PrP-molecule, that are tagged in such a fashion that the tag 
itself is converted into the PK-resistant part of the prion molecule. It has been shown 
numerous times that tagging of the prion protein, using either C- or N-terminal myc, 
GFP or tap-tags, leads to an inhibition of the prion conversion reaction (Bian et al., 
2006). Furthermore, no mice expressing a tagged, convertible versions of the prion 
protein are available or has been reported in the literature. Our method can be used to 
study prion replication in any transgenic mouse or cell type that can be infected with 
ΔC(RML). In essence, as long as ΔC(RML) is compatible with the host-PrP molecule 
(e.g. murine PrPC), this technique should be applicable. Other applications for such an 
assay could be imagined. This setup could be used to confirm the controversial 
observation by Vorberg et al. suggesting that newly generated PrPSc can be detected in 
cells within hours after a prion infection (Vorberg et al., 1999). In addition, I 
speculate that the technique can be used to set up a simplified SCEPA assay, that does 
not require the many cell passages normally needed for a specific detection of prions. 
This simplified assay could be used for drug or genetic screening of factors interfering 
with prion infection/replication (Klohn et al., 2003; Solassol et al., 2003; Bertsch et 
al., 2005). 
 
Cells supporting prion replication in the CNS 
An important parameter for understanding prion replication and pathogenesis in the 
CNS is to assign specific functions to the various CNS cell populations. For instance, 
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microglia have commonly be linked to pathology, by suggesting that microglia-
mediated inflammation could play a causal role in neurotoxicity (Baker and 
Manuelidis, 2003). Another important parameter is to understand which cells 
contribute to prion propagation. Different approaches has been used to characterize 
which cells replicate prions in vivo. The main approach has been to generate 
transgenic mouse lines expressing PrPC under cell specific promoters on a Prnpo/o 
background. Mice expressing the hamster prion protein under the neuron specific 
enolase promoter (NSE-PrP) were susceptible to hamster prions and came down with 
disease only with a slight delay, showing that neuronal PrP expression is sufficient to 
support prion replication and prion pathogenesis (Race et al., 1995). However, similar 
mice expressing the hamster PrP transgene under the astrocyte specific glial fibrillary 
acidic promoter (GFAP), also replicated prions and developed pathology (although 
with a delay) upon infection with hamster prions (Raeber et al., 1997). These studies 
was complemented by 2 excellent studies by the Collinge group, showing that 
conditional neuronal deletion of the prion protein post-infection can reverse early 
prion pathogenesis (spongiosis) and behavioral deficits (Mallucci et al., 2003; 
Mallucci et al., 2007). In these mice, PrP is deleted from neurons, but not glia cells 
using the Cre-LoxP system, at a time post-inoculation where the mice show PrPSc 
accumulation and spongiosis. Despite the fact that the mice eventually develop 
abundant PrPSc accumulation (PrPSc replicate by glia cells) and a strong gliosis, these 
mice fail to develop any prion-associated pathological changes (Mallucci et al., 2003). 
These results, together with the results from the NSE-PrP mice, suggests that although 
prion replication does take place on astrocytes, prion replication in neurons are both 
necessary and sufficient for the development of prion pathogenesis. In contrast to 
these studies, PrP expression under the oligodendrocyte/Schwann cell specific 
promoter, the myelin basic protein (MBP), does not support prion replication (Prinz et 
al., 2004). 
Another approach to study cell-specific prion replication is to investigate cultures of 
homogeneous cell populations purified from mice. Previously, only 3 groups has 
reported successful infections of primary post-natal CNS-derived cells (Cronier et al., 
2004; Giri et al., 2006; Milhavet et al., 2006). These groups reported that dividing 
neural stem cells and neurospheres can be prion infected (Giri et al., 2006; Milhavet et 
al., 2006). Furthermore, astrocytes and CGC neurons could be infected and prion 
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replication induced a small increase in granule cell apoptosis, suggesting that prion 
induced cell death is cell autonomous (Cronier et al., 2004). While immortalized 
microglia from PrP-overexpressing mice was capable of supporting prion replication, 
primary microglia, even from tga20+/+ mice failed to replicate prions (Iwamaru et al., 
2007). This is possibly due to their low expression of PrPC (Baker et al., 2002). In a 
similar fashion, it was shown that cell lines derived from peripheral glia cells 
(Schwann cells) are also capable of replicating prions (Follet et al., 2002; Archer et 
al., 2004). Whether Schwann cells themselves replicate prions is a different matter 
entirely, and yet to be determined. 
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OUTLOOK 
 
I am currently continuing to test which CNS and PNS-derived primary cells can be 
infected in vitro. Oligodendrocytes, Schwann cells and peripheral neurons are being 
tested to determine their prion replication competence. In addition, other people in the 
Aguzzi lab are testing other peripheral cell types involved in prion transport and 
neuroinvasion. I plan to use the invisible inoculum to determine if early prion 
replication within hours does take place in vitro and in vivo (Vorberg et al., 2004). 
Furthermore, I plan to test if the ΔC(RML) inoculum can be used for a simplified 
SCEPA assay (Klohn et al., 2003). Finally, I am trying to determine if the deletion of 
a part of the N-terminus of the prion protein confers new strain properties by 
comparing the original RML inoculum to RML passaged in ΔC mice using various 
biochemical and biophysical tools. 
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Materials and Methods 
Mice 
All mouse experiments were performed according to Swiss federal regulations. The 
pups used for most experiments were F1 offspring of tga20+/+ Prnpo/o males on a 
129SV/BL6 background crossed to heterozygous CD11b-HSVTK females (tg620) on 
a C57BL/6 background (Heppner et al., 2005). I refer to the Prnp+/o tga20+ HSVTK 
transgene-negative offspring as tga20TK and the transgene-positive littermates as 
tga20TK+. Prnpo/o, Prnp+/o, Prnpo/o tga20+ and CD11b-HSVTK mice backcrossed to 
Prnpo/o for 6-8 generations (Prnpo/o/TK) were all on a 129SV/BL6 background. 
CD11b-HSVTK (tg620) and GFAP-HSVTK mice (line 7.1) were all on a C57BL/6 
background and were genotyped as previously described (Bush et al., 1998; Heppner 
et al., 2005). 
 
Prion strains 
Rocky Mountain Laboratory strain passage-6 (RML6) was amplified in CD-1 mice, 
ME7 in 129/Sv mice,  5193/1 in tga20 mice and 22F, 79A, 87A, 87V, 139V, 301V, 
5192/2 and 301C (murine-adapted BSE) were all amplified in C57BL/6 mice by 
intracerebral inoculation of 30 μl, 10 % brain homogenate. RML passaged once into 
ΔC (C4/C4) mice were obtained (a kind gift from Eckhard Flechsig) and further 
transmitted for a second passage into C4/C4 mice. The primary ΔC(RML) passage 
was used for all experiments. 
 
Organotypic cerebellar slice cultures 
Organotypic cerebellar slice cultures were prepared according to a modified version 
of a protocol by Stoppini et al (Stoppini et al., 1991). In brief, the cerebellum was 
obtained from 9-12-day old pups. Brain tissue was embedded in 2 % (w/v) Ultra-low 
melting point agarose dissolved in Gey’s balanced salt solution (GBSS) (NaCl 8 
g/l, KCl 0.37 g/l, Na2HPO4 0.12 g/l, CaCl2·2H20 0.22 g/l, KH2PO4 0.09 g/l, 
MgSO4·7H20 0.07 g/l, MgCl2·6H20 0.210 g/l, NaHCO3 0.227 g/l) supplemented with 
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the glutamate receptor antagonist kynurenic acid (1 mM) (GBSS-K). Liquid agarose 
(kept at a constant temperature 37 °C using a water bath) was transferred to a small 
container, the isolated brain tissue was submerged and the tissue block was cooled on 
ice until the agarose solidified (10 min). The block was mounted (glued) onto a 
specimen disc and 350 μm thick slices were cut on a vibratome (VT1000, Leica-
microsystems) while submerged in a cooled reservoir (4 °C) containing GBSS-K. 
Slices were transferred in a small volume of GBSS-K to Millicell-CM BioporeTM 
PTFE membrane inserts (Millipore), using the blunt end of a sterile Pasteur pipette. 
Residual GBSS was removed and the inserts were transferred to a cell culture plate 
and cultured for up to 5 weeks in slice culture medium (50 % MEM, 25 % BME and 
25 % horse serum supplemented with 0.65 % glucose, penicillin/streptomycin (1x) 
and Glutamax (1x) (Invitrogen). Cultures were kept in a standard cell incubator (37 
°C, 5 % CO2 and 95 % humidity) and 80 % of the culture medium was exchanged 3 
times a week. 
 
Prion Organotypic Slice Culture Assay (POSCA) 
In order to prion infect the tissue cultures, slices were prepared and transferred to 24-
well plates in a small volume of GBSS-K. Cultures were treated as free-floating 
sections with various concentrations of prion-infected or mock brain homogenates 
(homogenized in PBS) diluted in 1 ml GBSS-K for 1 h at 4 ºC. Slices were washed 
twice by transferring the slices in a small volume of GBSS-K (approximately 0.5 ml) 
to a reservoir containing 6 ml fresh GBSS-K buffer. Finally, 5-10 slices were 
transferred to a 6-well Millicell-CM BioporeTM PTFE membrane insert (Millipore) 
(For staining experiments, 1-2 slices were placed on a 24-well insert) and all excess 
buffer was removed.  
 
Macrophage reconstitution of microglia depleted slices 
For reconstitution of microglia-depleted slices, intra-peritoneal macrophages were 
obtained. Mice were euthanized and the abdominal skin was removed without 
disturbing the peritoneal cavity. 5 ml ice-cold PBS was injected into the peritoneal 
cavity using a 25-gauge needle. After massaging the abdomen macrophages was 
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recovered and cells were counted using 0.4 % Trypan blue. Organotypic cerebellar 
slice cultures were reconstituted immediately after preparation, by adding 250.000 
macrophages to each insert (10 slices/6-well insert) and GCV-treatment was initiated. 
GCV was added to a final concentration of 5 μg/ml, a concentration previously shown 
to be optimal for microglia depletion in vitro (Heppner et al., 2005). 
 
Preparation of enriched mono-cultures 
Mixed glial cultures were prepared from 1-2 day old mice according to a standard 
protocol (Giulian D, 1986). Cells were cultured in DMEM supplemented with 20 % 
heat inactivated FBS, antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) 
and 2 mM GlutaMax. After 1 week in culture, the serum concentration was lowered to 
10 % and this medium was used for all subsequent experiments. After 14 days the 
confluent cultures were shaken vigorously to dislodge microglia and oligodendrocyte 
precursor cells from the astrocytic monolayer. For infection of microglia cells, 
floating cells were collected and seeded onto a feeder layer of GCV-treated 
Prnpo/o/TK+ astrocytes in a 25-cm2 flask. 40 minutes after seeding the cells, medium 
was exchanged to remove oligodendrocytic-precurser cells and cultures were infected 
with ΔC(RML). At the time of harvest, microglia were shaken off the astrocyte and 
collected by differential adhesion to a plastic dish. Microglia purity > 98 % was 
routinely obtained as measured by staining using Alexa fluor 594 conjugated 
Isolectin-B4 from griffonia simplicifolia (Molecular Probes). The astrocytic 
monolayer was washed in Ca2+/Mg2+ free Hanks buffered saline solution and split 
using Trypsin/EDTA. Cells were re-seeded in 12-well plates at a density of 50.000 
cells/well, infected with ΔC(RML) and cultured in the presence of GCV.  
Cerebellar granule neurons were cultured from 7-day old mice according to (Leist M, 
1997). In brief, 7-day old mice were decapitated and the cerebellum was collected. 
The cerebellar meninges were removed and the tissue was digested with trypsin and 
Dnase-1. After trituration, cells were counted and seeded on Poly-L-lysine (100 
μg/ml) coated 24-well plates at a density of 400.000 cells/well and after 45 min, 
medium was exchanged to decrease the number of glia in the culture. Cells were 
cultured for 1 day in BME supplemented with 10 % FCS, 1 mM Glutamax, 100 U/ml 
penicillin and 100 μg/ml streptomycin. After 24 h, the medium was exchanged to 
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serum-free medium, neurobasal medium, supplemented with 1 mM Glutamax, 100 
U/ml penicillin, 100 μg/ml streptomycin and B27-supplement. Cultures were infected 
with ΔC(RML) immediately after seeding or after the first medium exchange. 
Ganciclovir (5 μg/ml) was added at the time of culturing and after 7 days in vitro.  
 
Western blot analyses 
Cultures were washed twice in PBS, residual PBS was removed and the tissue was 
scraped off the membrane using 10 μl lysis buffer per slice (0.5 % sodium 
deoxycholate and 0.5 % Nonidet P-40) or PBS. Tissue was lysed by 3 freeze-thaw 
cycles and triturated using a 200 μl pipette until homogeneous. For samples that were 
transferred to the SCEPA, samples were harvested in PBS, triturated using a 29-G 
needle, followed by 30 sec sonication.  Each sample consisted of a pool of 5-10 slices 
grown on the same insert, yielding approximately 2-350 μg protein in total. Protein 
concentration was determined using the bicinchoninic acid assay (Pierce) and the 
tissue was digested with PK (Roche) in lysis buffer for 30 minutes at 37 °C. PK-
resistant material was detected as a standard by digesting 20 μg protein lysate with 25 
μg/ml PK. This condition was more sensitive as compared to using higher PK 
concentrations, but still allowed for specific detection of PrPSc. For analysis of prion-
infected mono-cultures, the lysis buffer were supplemented with 1 mM 
ethylenediamine tetraacetic acid (EDTA) and 100 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, pH 7.0). 8-10 μg protein was digested with 5 
μg/ml PK. PK digestion was stopped by adding loading buffer (NuPAGE, Invitrogen) 
and boiling the samples at 95 °C for 5 minutes. Proteins were separated on a 12 % 
Bis-Tris polyacrylamide gel (NuPAGE, Invitrogen) and blotted onto a nitrocellulose 
membrane. Membranes were blocked with 5 % Topblock (Fluka) in PBS and 
incubated with primary antibodies in 1 % Topblock. Primary antibodies used were 
mouse α-PrPC IgG1 (POM-1),  mouse α-PrPC IgG1 (POM-12),  200 ng/ml, ascites 
fluid of mouse α-Glial Fibrillary Acidic Protein (GFAP) IgG1 (Clone GA5) 1:3000 
(Sigma-Aldrich) and goat α-human Iba1, 0.5 μg/ml (Wako). Secondary antibodies 
used were horse radish peroxidase-conjugated (HRP) rabbit α-mouse IgG1, 1:10,000 
(Zymed), HRP-conjugated rabbit α-goat IgG1, 1:10,000 (Zymed) and HRP-conjugated 
swine α-rabbit IgG, 260 ng/ml (DAKO). The blots were developed using 
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SuperSignal® West Pico Chemiluminescent substrate (Pierce) and detected using the 
VersaDoc system (model 3000, Biorad). The molecular weight marker was spiked 
with recombinant PrPC yielding a PrP-signal at 23 kDa, with a degradation product at 
15 kDa. 10 μl marker were loaded in the left lane on all blots. 
Cell death measurements  
Propidium Iodide (PI) incorporation was measured by incubating the slices with PI 
(10 μg/ml, Molecular Probes) for 15 minutes. Images were acquired using a 
fluorescent microscope (Axiovert 200M equipped with Axiocam HRm, Zeiss) and 
images were analyzed using image analysis software analySIS© vs5.0 (Olympus Soft 
Imaging Solutions GmbH, Münster, Germany). All images were acquired using the 
same exposure times and analyzed using the same software settings within a region of 
interest (the total area of tissue present in the image). After recording fluorescent 
images, the tissue was washed in PBS and lysed in PBS, 0.5 % Nonidet-P40, 0.5 % 
DOC and 5 mM 1,4-dithiothreitol. Caspase-3 Fluorometric Correlate-Assay (Assay 
designs) was used to determine caspase-3 DEVDase activity according to the 
manufacturers instruction. In brief, protein lysates were incubated with the 
fluorogenic caspase-3 substrate, Ac-DEVD-7-Amino-4-methyl coumarin, and 
enzymatic cleavage by caspase-3 was quantitated by kinetic measurements (1 
measurement every 2 minutes for 2 hours) using a fluorometer. The specific caspase 
activity was calculated from a standard curve generated using recombinant caspase-3 
with a known enzymatic activity and normalized to the protein content. One unit of 
caspase-3 activity is defined as the amount of enzyme needed to convert 1 picomol of 
substrate per minute at 30 ºC. 
 
Enzyme-linked immunosorbent assay (ELISA) and nitrite measurement 
Organotypic hippocampal slice cultures (OHSCs) were prepared from 12 day old 
mice, and treated with 5 µg/ml GCV for the duration of the experiment. After 7 days, 
activation of microglia was initiated by adding recombinant murine IFN-γ (10 ng/ml, 
R&D systems) and LPS from Salmonella abortus equi (1 µg/ml, Bioclot). To assess 
nitric oxide, cytokines and chemokines, cell culture supernatant was harvested 48 h 
after LPS/IFN-γ stimulation except for TNF measurements, where supernatant was 
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taken after 8 h. Each group contained of 3–4 inserts with 4 OHSCs on each insert. 
Supernatants derived from OHSCs were analyzed by the use of ELISA kits for TNF-
α, IFN-γ (Pharmingen) or MIP-1β (R&D systems) according to the manufacturer’s 
instructions. Nitrite was measured with the Griess reagent. 50 µl supernatant or 
NaNO2 standards were mixed with 25 µl N-(1-naphthyl)ethylenediamine (0.1 % in 
H2O) and 25 µl sulfanilamide (1 % in 1.2 N HCl) in a 96 well plate and the optical 
density was assessed after 3 min at 570–690 nm. To include the contribution of the 
NO metabolite nitrate, 50 µl vanadium(III) chloride (8 mg/ml in 1 M HCl) was added 
to the Griess reagent and incubated at 37°C for 30 min (Miranda et al., 2001). 
 
Immunohistochemistry  
Histoblot analysis was performed according to a standard protocol using 50 μg/ml PK 
(30 min, 37 °C) (Taraboulos et al., 1992). For immunohistochemistry the tissue was 
fixed in 2 % PFA, o/n at 4 °C. Membrane inserts were washed and incubated for 1 h 
in blocking buffer (0.1 % Triton X-100 and 2 % goat serum dissolved in PBS) and 
incubated for 2-5 days with primary antibody diluted in blocking buffer. Primary 
antibodies and concentrations used were ascites fluid of mouse α-chicken calbindin 
IgG1 1:2000 (Swant), rabbit α-mouse neurofilament-M polyclonal antibody 1:400 
(Chemicon), rabbit α-mouse GFAP polyclonal antibody 1:1000 (DAKO), mouse α-
frog parvalbumin IgG1 antibody 1:500 (Sigma-Aldrich), mouse α-human βIII-tubulin 
IgG1 1:1000 (Chemicon), rat α-mouse CD68 IgG2a, 1 μg/ml (Serotec) or ascietes fluid 
of rat α-bovine MBP IgG2a 1:250 (Serotec). The primary antibodies were detected 
using Alexa-conjugated secondary antibodies (4 μg/ml) (Molecular Probes) and 
counterstained with dapi (1 μg/ml). Microglia were detected in fixed and in live tissue 
by staining with IB4 (Griffonia Simplicifolia) (2-4 μg/ml) (Molecular Probes). The 
culture membranes were removed from the inserts and mounted directly onto a 
microscope slide using fluorescent mounting medium (DAKO). Images were acquired 
in a focal plane 35-40 μm below the tissue surface using a laser-scanning confocal 
microscope (SP 2, Leica), by fluorescent microscopy (Axiovert 200M, Zeiss) or for 
live imaging studies by using wide-field microscope (DM IRBE, Leica) equipped 
with a temperature controller and a CO2 box (37 °C and 5 % CO2). Incorporation of 5-
bromodeoxyuridine (BrdU) into the tissue was assessed after a 24 h incubation with 
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25 μg/ml BrdU. DNA was denatured by treatment with 1 N HCl for 1 h at 37 °C, 
followed by 2 x 30 min neutralization steps with 0.1 M Borate (pH 8.5) and 2 washes 
in PBS. The tissue was subsequently stained with 15 μg/ml mouse α-
bromodeoxyuridine IgG1 (clone BU-33, Sigma) and rat anti-mouse CD68 according 
to normal procedures. Monocultures were stained according to a similar protocol, but 
with only 15 min fixation, 5 min permeabilisation, o/n incubation with primary 
antibody, and 1 h incubation with secondary antibody. All counting was performed 
manually, assisted by image analysis software analySIS© vs5.0. 
 
Quantitative PCR  
Organotypic slice cultures were prepared and incubated as previously stated. Cultures 
were washed once with PBS and total RNA was extracted using TRIzol reagent 
(Invitrogen Life Technologies) according to the manufacturer’s protocol. Before 
cDNA synthesis residual genomic DNA was removed using the DNA-free kit 
(Ambion) and cDNA was synthesized from 1 μg total RNA with QuantiTect reverse 
transcription kit (Qiaqen) using random hexamers according to the manufacturer’s 
protocol. Successful cDNA synthesis and contamination of total RNA with genomic 
DNA was tested by PCR with primers specific for Actb. Quantitative real-time PCR 
was performed using the SYBR Green PCR Master Mix (Applied Biosystems) on an 
ABI PRISM 7700 Sequence Detector (PerkinElmer). Fold regulation was calculated 
relative to untreated transgene-negative slices (wt) after normalization to the β-actin 
signal. The following primer pairs were used: Actb sense (NM_007393): 5’-GAC 
GGC CAG GTC ATC ACT AT-3’, antisense: 5’-ACA TCT GCT GGA AGG TGG 
AC-3’. Itgam sense (NM_008401): 5’-GAC TCA GTG AGC CCC ATC AT-3’, 
antisense 5’-AGATCG TCT TGG CAG ATG CT-3’. MBP (NM_010777) and Nefh 
(NM_010904) were detected using the commercially available QuantiTect primer 
assay (Qiagen). 
 
Scrapie cell assay in endpoint format (SCEPA)  
Prion-susceptible neuroblastoma cells (subclone N2a-PK1) were exposed to brain 
homogenates in 96-well plates for 3 days. Cells were subsequently split 3 times 1:3 
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every 2 days, and 3 times 1:10 every 3 days. After confluence was reached, 25.000 
cells from each well were filtered onto the membrane of an ELISPOT plate, treated 
with PK, denatured and individual infected (PrPSc-positive) cells were detected by 
immunocytochemistry using alkaline phosphatase-conjugated POM-1 mouse anti-PrP 
antibody and alkaline phosphatase conjugate substrate kit (Biorad). Serial ten-fold 
dilutions were performed in cell culture medium containing healthy mouse brain 
homogenate. Scrapie-susceptible N2a-PK1 cells were then exposed to dilutions of 
experimental samples ranging from 10-3 to 10-6, or a 10-3 dilution of healthy mouse 
brain homogenate (“mock”) or RML6. Samples were quantified by total luminescence 
per well or in end-point format by counting positive wells according to established 
methods (Klohn et al., 2003). 
 
Statistical analysis  
One-way ANOVA with Bonferroni post test for selected pairs of columns was used 
for statistical analysis of experiments involving the comparison of 3 or more samples. 
Paired student T-test was used for comparing 2 samples. Results are displayed as the 
average of replicas ± standard deviation. 
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Supplementary Figure 1: Video microscopy of microglia depletion. Slices prepared 
from CD11b-HSVTK+ mice were treated with GCV for 8 days and IB4 was added to 
the cell culture medium. Images were recorded on a wide-field fluorescent 
microscope every 30 minutes for 5 days and the video is shown at a rate of 10 
frames/s.
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